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ABSTRACT

Nucleic acid bioconjugates have gained widespread use in medicinal chemistry research
programs aimed at fighting human malignancies such as cancer, diabetes, genetic and infectious
diseases. Their popularity stems from their ability to accelerate the drug development process by
conjugating chemical functionality that may improve the pharmacology of a bioactive
nucleoside. Moreover, this strategy has been proven to be effective with small molecule
nucleoside analogs and those derived from lengthy oligonucleotide sequences. Considering these
fruitful applications, my research and this thesis aims to explore the synthesis, characterization
and therapeutic potential of novel classes of nucleic acid bioconjugates.
These are based on, aminoacyl nucleolipids, from which a simple, versatile and efficient
synthesis strategy has been developed for this new class of DNA binding molecules as described
in Chapter 2 of this thesis. This bioconjugate exhibited GRP78 oncogene binding affinity (KD:
0.25 mM) as characterized by PAGE gel shift assays. Its binding affinity towards the GRP78
oncogene was also confirmed using circular dichorism spectroscopy, and thermal denaturation
experiments. Moreover, dynamic light scattering experiments also demonstrated increases in
particle sizes after binding of this molecule to the GRP78 oncogene. In a single dose (10 µM)
screen against a panel of 60 cancer cell lines, the aminoacyl nucleolipid demonstrated selective
anti-leukemic activity, highlighting its potential in anti-cancer research programs.
In Chapter 3, the synthesis, biophysical properties and GRP78 DNA cleavage activity of
a phthalocyanine-linked oligonucleotide will be highlighted for photodynamic oncogene therapy
applications. The synthesis and characterization of cancer-targeting oligonucleotide (CTO) and
its

bio-conjugation

to

a

chemically

resilient

photosensitizer,

a

carboxy-derived

perfluorophthalocyanine (Pc), enabled the production of a unique bioconjugate for potential antiiv

cancer applications. In this study, the Pc-CTO demonstrated the ability to hybridize to
complementary GRP78 DNA and mRNA oncogenes. In a photochemical oxidative cleavage
assay, the Pc-CTO triggered significant degradation of the GRP78 oncogenes underscoring its
potential in GRP78-targeting photodynamic therapy.
In Chapter 4, a study into the design, synthesis and structure-function relationships of a
new class of nucleic acid bioconjugates is presented. The diacylhydrazine-linked dinucleosides
represent a novel class of nucleic acid bioconjugates that are proposed to improve the structural
stability of turn conformations in DNA or RNA hairpin secondary structures. My advances in the
synthesis, structure elucidation and biological evaluation of these putative hairpin mimics will be
described. In sum, this thesis will serve to highlight my contributions to the flourishing field of
nucleic acid bioconjugation for GRP78-targeting for anti-cancer applications.
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CHAPTER 1: ANTI-CANCER APPLICATIONS OF NUCLEIC ACID
BIOCONJUGATES
1.1 GENERAL INTRODUCTION OF NUCLEIC ACID BIOCONJUGATES AND THEIR
RELEVANCE IN CANCER THERAPY
Genetic mutations can be the origin of tumorigenesis, unleashing a myriad of signaling
pathways that leads to protein overexpression, unregulated cell growth and differentiation. This
aberrant activity is followed by tumor invasion and metastatic spread to a variety of tissues and
organs. At this stage, tumors are typically too lethal to treat by common surgical procedures or
localized chemotherapy and radiation treatments [1]. Therefore, combination approaches are
rapidly emerging in a last ditch effort to save patients that have been diagnosed with incurable
forms of tumors. Combination therapy is based on prescribing multiple chemotherapeutic drugs
or combining chemotherapy with other treatment methods such as radiation and related
photodynamic therapies. These synergistic approaches have proven to be highly effective by
compromising multiple pathways of tumor progression, triggering cancer cells death while
minimizing toxicities, drug resistance and tumor recurrence [2]. In recent years, modified nucleic
acids have gained widespread use as cancer therapeutics. This trend has chemical origins, which
facilitates the incorporation of modification without restriction to improve the therapeutic
properties of the bioactive nucleic acids. For example, small molecule-nucleoside conjugates,
small interfering RNA (siRNA), antisense oligonucleotides (AON), and short hairpin DNA/RNA
(shDNA/RNA) have all been successfully applied for cancer therapy in-vivo [3–5]. Historically,
the majority of this research has focused on targeting a single oncogene or oncoprotein limiting
the full potential of modified nucleic acids in cancer therapy. In order to improve the power of
nucleic acids in cancer therapy, bioconjugation approaches have been explored and developed.
These include the combination of modified nucleic acids with small molecule drugs, or other
1

treatment and/or imaging modalities [3,5]. In this manner, modified nucleic acids own the
potential for targeting multiple biological markers in tumors leading to synergistic anti-tumor
responses. Consequently, tumor resistance and recurrence is limited en route towards an effective
form of cancer therapy. For the widespread adoption of nucleic acids in clinical applications,
effective delivery strategies are necessary to shield nucleic acids from ubiquitous nuclease
degradation and to facilitate cellular penetration. Towards this effect nucleic acid delivery
systems based on polyplexes, nanoparticles, liposomes, and micelles, have been formulated to
enhance their pharmacokinetic properties [6]. Recent advances in materials design and synthesis
has facilitated the production of biocompatible nanocarriers that are capable of delivering drug–
nucleic acid combinations with exquisite cancer cell selectivity and controlled delivery for potent
anti-cancer responses [7]. This has led to the first human clinical trials (Figure 1.1) of
siRNA:lipid nanoparticles (siRNA:LNP) targeting the vascular endothelial growth factor
(VEGF) and kinesin spindle protein (KSP) in humans diagnosed with liver cancer [8].

Figure 1.1. siRNA:LNP complexes for combination therapy in human cancer clinical trials.
Figure adapted from Tabernero, J.; Shapiro, G.I.; LoRusso, P.M.; Cervantes, A.; Schwartz,
G.K.; Weiss, G.J.; Paz-Ares, L.; Cho, D.C.; Infante, J.R.; Alsina, M.; Gounder, M.M.; Falzone,
2

R.; Harrop, J.; White, A.C.; Toudjarska, I.; Bumcrot, D.; Meyers, R.E.; Hinkle, G.; Svrzikapa,
N.; Hutabarat, R.M.; Clausen, V.A.; Cehelsky, J.; Nochur, S.V.; Gamba-Vitalo, C.; Vaishnaw,
A.K.; Sah, D.W.; Gollob, J.A.; Burris, H.A. Cancer Discov. 2013, 3, 406-417.
[8].
1.2 SMALL MOLECULE NUCLEIC ACID BIOCONJUGATES IN CANCER THERAPY
Recent advances in chemical methods for nucleic acid synthesis has enabled the
development of nucleic acid bioconjugates. In this presentation, nucleic acids encompass the
core of the bioconjugate, with the terminal hydroxyl groups (2’, 3’ and 5’-OH) presenting the
points of attachment with other bio-active molecules or functional groups (Figure 1.2).

Figure 1.2. Terminal hydroxyl groups (2’, 3’ and 5’-OH) on the nucleic acid core that can serve
as possible points of attachment with other bio-active molecules or functional groups..
Furthermore, the hydroxyl groups may also be selectively modified to other functional
groups (amino, thiol, carbonyl and carboxylic acids) to facilitate conjugation with stable or
reversible covalent bonds [9]. The latter has been especially useful in the development of nucleic
acid pro-drug approaches [10]. Other synthetic approaches have been developed, incorporating
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chemical modifications on the nucleobases using azide-alkyne Huisgen cycloaddition chemistry
[11], ring-opening reactions of the carbohydrate [12], and replacement of the phosphate group
through various functional group transformation reactions [13]. Thus, nucleic acids may be
readily derivitized by chemical synthesis to yield bio-active compounds for cancer therapy [14]
Figure 1.3.

Figure 1.3. General structural and chemical modifications of nucleoside and nucleotide
analogues. Nucleoside and nucleotide analogues consist of a nucleobase (a purine or pyrimidine
derivative) and nucleotides have a phosphate group (P) linked to sugar moiety. The chemical
diversity of these compounds is based on chemical reactions including halogenation, azotation,
protection by polar groups and other chemical modifications (Figure adapted from reference 14).

For example, adenine deoxynucleosides cladribine (2CdA, 1.1) and fludarabine (FAraA,
1.2) have been shown to damage DNA by interfering with DNA replication and repair
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mechanisms leading to caspase-dependent apoptosis by activation of the mitochondrial cell death
pathways in rapidly proliferating lymphoid cells [15]. Modified thymidine-based nucleoside,
sapacitabine (1.3) has been used in human clinical trials for the treatment of acute myeloid
leukemia [16]. In the bone marrow of peripheral blood acute myeloid leukemia cells,
sapacitabine, 1.3, has been shown to induce cell cycle arrest in the G2 phase following a delayed
S phase [19]. Its mechanism of action is based on kinase activation and incorporation within
DNA during DNA polymerase assisted chain elongation. The electron withdrawing C2’-cyano
group triggers the elimination of the vicinal 3’-OH group, preventing DNA polymerization and
inducing a strand scission which is minimally repaired by DNA polymerase leading to cell death.
Gemcitabine (1.4) has been used to treat lethal forms of solid pancreatic tumors, often with
success when used in combination with other chemotherapeutics such as 5-flurouracil (1.5), [17].
Its mechanism of action is partly based on its high accumulation within cells. This results in
efficient substrate-level phosphorylation, where it acts as an inhibitor of ribonucleotide reductase
and a substrate for DNA polymerase where it terminates DNA synthesis and thereby stimulating
apoptosis [20]. The pro-drug cytidine-based phosphoramide, NUC-1031 (1.6) has been
administered to cancer patients that have grown resistant to gemcitabine (1.4) [18]. In this
instance, tumor resistance towards gemcitabine (1.4) can be intrinsically acquired or developed
with prolonged treatment methods. The intracellular uptake of gemcitabine (1.4) and related
nucleosides is dependent on the cell surface overexpression of nucleoside transporters (eg.
hENT-1), which have been found to be suppressed in gemcitabine (1.4) resistant tumor cell lines
[21]. Overcoming tumor resistance with the incorporation of chemical modification has recently
enabled an analog of gemcitabine (1.4), NUC-1031 (1.6), to exhibit significant reduction in
tumor volumes in pancreatic cancer xenograft mice models. This analog is currently in Phase I/II
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clinical testing and presents itself as a promising lead in resistant tumor models [22]. Thus,
chemical modifications in small molecule nucleoside analogs have been successful in translating
biologically active nucleosides from pre-clinical to bed side use in cancer therapy (Figure 1.4).
Despite their growing clinical potential, they are still plagued by widespread toxicology profiles
as these types of non-specific chemotherapeutics are dispersed in all tissue types. Therefore, the
need for new and improved forms of cancer therapy are currently in high demand, in the hope of
eradicating the most morbid and resilient types of tumors with cancer-targeting approaches.

Figure 1.4. Chemical structures of anticancer nucleoside and nucleotide analogues in clinical
applications. 2CdA, 1.1, FAraA, 1.2 and 5FU, 1.5 are nucleoside analogs; sapacitabine, 1.3 is a
6

nucleoside-fatty acid conjugate; NUC‑1031, 1.6, is a prodrug bioconjugate of gemcitabine, 1.4
[15-18].
1.3 CANCER-TARGETING THERAPY WITH OLIGONUCLETIDE BIOCONJUGATES
Bioconjugation approaches of oligonucleotides have gained widespread interest due to
the unrestricted ability to introduce chemical or biological functionality that may improve the
therapeutic properties of modified oligonucleotides (MONs). These types of nucleic acid
bioconjugates are based on an oligonucleotide scaffold (natural or modified) and a linker that
functions to connect the oligonucleotide moiety to the bio- or chemically active component
(Figure 1.5). Moreover, the oligonucleotide strand may be composed of base sequences that
enable specific recognition and binding to a complementary RNA, DNA or nucleic acid binding
proteins. In this manner, the oligonucleotide functions as a targeting vector for the selective
treatment of oncogene or oncoproteins in cancer. The choice of the linker is also very important
because its length and composition typically influences the biological activity of the conjugated
components. Additionally, the linker may also impart favorable solubility properties, such as
fine tuning the hydrophobicity of the polar ionic oligonucleotide strand. It may also effect
oligonucleotide flexibility or rigidity, respectively based on the linear or cyclic linker moieties.
In spite of the linker’s utility, the power of oligonucleotide bioconjugates ultimately resides
within the oligonucleotide targeting vector and the conjugated components which functions in a
synergistic manner to improve the therapeutic potential of oligonucleotides.
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Figure 1.5. Rational design of an oligonucleotide bioconjugate
1.3.1 SYNTHESIS OF OLIGONUCLOETIDES
Solid phase synthesis methods have been developed to allow for the small scale synthesis
(µg-mg quantities) and preparative scale production (g-kg quantities) of oligonucleotides for
applications in chemical biology, gene therapy and biotechnology [23]. For all these purposes,
oligonucleotides are manufactured almost exclusively using automated solid phase synthesis
methods [24,25]. The automated solid phase oligonucleotide synthesis cycle (Scheme 1.1)
begins with a detritylation step, for the removal of the 5’-DMT group from the building block
DNA or RNA monomer linked to the controlled pore glass (CPG) solid support, 1.7. The
detritylation step is performed to completion with 3% dichloroacetic acid in dichloromethane,
3% DCA : DCM, followed by a DCM wash cycle to remove any residual acid prior to the
coupling step. The DNA or RNA phosphoramidites (Scheme 1.1) are the monomers that
lengthen the oligonucleotide strand during the coupling step of the solid phase synthesis cycle.
They are dissolved in anhydrous acetonitrile, MeCN, and coupled to the growing oligonucleotide
with 0.25 M 5-ethylthiotetrazole, ETT, in MeCN. Typical coupling times for RNA synthesis are
on the order of 10 - 15 minutes while DNA synthesis occurs in 2-5 minutes. This discrepancy is
due to the bulky 2’-OTBDMS protecting groups used in the RNA synthesis cycle. Following
coupling, the dinucleotide bound support, 1.10, is washed with MeCN and capped to prevent
8

elongation of failure sequences during the synthesis cycle. This capping step is performed with a
solution (Cap A: 1:1:8 v/v/v acetic anhydride:pyridine:tetrahydrofuran, Cap B: 16% N-methyl
imidazole in tetrahydrofuran) which acetylates any unreacted 5’-OH and prevents side reactions
with the uncoupled nucleoside bound support, 1.11. During the course of the synthesis procedure
this step generates failure sequences; short oligonucleotide fragments that must be removed
during purification. Fortunately, each automated synthesis cycle for RNA is optimized to about
97-98% efficiency, while that of DNA typically occurs on the order of >98% such that the
accumulation of failure sequences is minimal. Following capping, an oxidation step with a 0.02
M oxidant (I2 in 75/20/5 v/v/v tetrahydrofuran/ pyridine/ water) converts the reactive phosphite
triester to the more stable phosphate triester backbone, 1.12. The support is then washed and
dried with MeCN and argon prior to 5’-detritylation and continuation of the synthesis cycle until
the desired sequence has been completed. Following synthesis, the oligonculeotide is cleaved
from the solid support, 1.13, and the phosphate cyanoethyl in addition to the nucleobase
protecting groups are removed using alkaline conditions, 1 : 1 v/v ammonium hydroxide:
methylamine (1 : 1 AMA) for 10 minutes at 65 oC. Of note, oligonucleotides which contain the
more resilient protecting groups (i.e. Gua N-iBu) require lengthier deprotection times, typically
accomplished with 3 : 1 v/v ammonium hydroxide in ethanol (3 : 1 NH4OH:EtOH) for 16 hours
at 55 oC. The alkaline solution is volatile and evaporated on a Speedvac® concentrator. The crude
oligonucleotide is then extracted from the CPG with autoclaved distilled water and quantitated
by UV-Vis spectroscopy using the Beer-Lambert law. For RNA samples, the oligonucleotide is
then concentrated and treated with a 1:1 v/v dimethylsulfoxide:triethylamine trihydrofluoride
(1:1 DMSO:TEA:THF, 125 µL) to complete the 2’-desilylation reaction at 65 °C for 90 min.
Following the 2’-desilylation reaction, RNA is precipitated using 3 M NaOAc (25 µL) in n-
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BuOH (1 mL), isolated by centrifugation and re-dissolved in autoclaved water for analyses and
purification using anion exchange, AE, [26] or reverse phase, RP, HPLC [27] and with
polyacrylamide gel electrophoresis, PAGE [28].

1.7

1.13

1.8

1.9

1.12

1.10
1.8

1.11
1.10

Scheme 1.1. Automated solid phase oligoncucleotide synthesis cycle. Figure adapted from
Wincott,

F.; DiRenzo,

A.; Shaffer,

C.; Grimm,

S.; Tracz,

D.; Workman,

C.; Sweedler,

D.; Gonzalez, C.; Scaringe, S.; Usman, N.. Nucleic Acids Res. 1995, 23, 2677-2684.
[24, 25].
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1.3.2

SYNTHESIS

AND

ANTI-CANCER

APPLICATIONS

OF

ANTISENSE

OLIGONUCLOETIDE BIOCONJUGATES
The antisense method for silencing gene expression originally implicated a short
tridecamer oligodeoxynucleotide d(A-A-T-G-G-T-A-A-A-A-T-G-G), which was complementary
to the Rous sarcoma virus 35S mRNA and led to potent inhibition of viral protein expression in a
cell-free system [29, 30]. The antisense mechanism of action (Figure 1.6) is based on a short (~
18-21 nucleotide base length) oligonucleotide ‘antisense’ strand with a sequence that is
complementary to the specific mRNA targeted for gene silencing. This antisense oligonucleotide
must penetrate the cell membrane to form a hybrid structure with the complementary sense
mRNA strand in the cytosol of the cell. Formation of the “antisense:sense” duplex inhibits
ribosome assembly for protein translation and/or elicits the binding of an RNaseH enzyme that
selectively hydrolyzes the RNA strand within the DNA:RNA duplex [31]. The antisense strategy
is highly efficient, necessitating minimal (pmol) quantities of antisense oligonucleotides in a
catalytic mechanism which recycles the antisense strand for potent and long-lasting gene
silencing effects in-vitro [29-31].

However, for useful applications in-vivo, antisense

oligonucleotides must exhibit efficient cellular delivery, nuclease resistance, regio-specific and
stable targeting and binding with a complementary mRNA sequence. These effects enable the
efficient recruitment of RNaseH activity with favorable pharmacokinetics properties and
minimal toxicities in cell based and animal models [32].
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Figure 1.6. Antisense mechanism of inhibiting mRNA protein translation. Figure adapted from:
Robinson R - RNAi Therapeutics: How Likely, How Soon? Robinson R PLoS Biology Vol. 2,
No. 1, e28 doi:10.1371/journal.pbio.0020028
Synthetic methods are necessary to convert the native oligonucleotide into a modified
oligonucleotide, MON, for potent antisense responses in-vivo. The MONs must possess
comparable binding and structural properties to their native DNA/RNA hybrids, while improving
nuclease resistance and cell penetration for efficient gene silencing responses within cells.
Bioconjugation methods have been introduced to improve the ‘drug-like’ properties of the
antisense oligonucleotides for various therapeutic applications [33,34], including those related to
silencing oncogene expression in cancer [35].
For example, the 5’-cholesterol

conjugate of an antisense phosphorothioate

oligonucleotide, 1.14, targeting the expression of the multidrug resistance (MDR) oncogene
associated with P-glycoprotein (Pgp) enhanced the accumulation of a Pgp rhodamine-123
12

substrate as indicated by flow cytometry and laser scanning confocal microscopy [36]. This
result is consistent with the rapid intracellular accumulation of the 5’-cholesterol antisense
oligonucleotide conjugate, which favors MDR knockdown and efficacy of anti-cancer drugs in
MDR mouse 3T3 fibroblasts. Moreover, replacement of the phosphodiester for a
phosphorothioate bond increases metabolic stability, allowing for lengthier therapeutic indices
during the MDR knockdown effect. In contrast, the unlabeled control triggered minimal Pgp
knockdown in MDR cancer cells and uptake of Pgp substrates due to the drug efflux properties
of the Pgp transporter. In this case, the non-polar cholesterol moiety enabled cellular uptake of
the antisense oligonucleotide, while the phosphorothioate preserved oligonucleotide stability
towards endonucleases, which enhanced the oncogene knockdown effect (Figure 1.7). The
phosphorothioates are introduced during the course of the automated solid phase synthesis cycle,
by replacing the oxidation step with a sulfurization reaction, 1.16, with 3-amino-1,2,4-dithiazole5-thione (ADTT) as efficient sulfur-transfer reagent [37]. The cholesterol moiety is coupled
during the last step of the synthesis cycle with a commercially available cholesterol
phosphoramidite, 1.15.

13

1.15

1.16

1.14

Figure 1.7. 5’-Cholesterol conjugate antisense phosphorothioate oligonucleotide, 1.14.
Bioconjugation of antisense oligonucleotides is especially favorable in combination
approaches, featuring specific silencing of oncogene expression by the antisense oligonucleotide,
coupled with potent anti-cancer effects of the conjugated drug. For example, Bcl-2 antisense
oligonucleotides sensitized radiation-induced fibrosarcoma 1 (RIF-1) cells to a silicon
phthalocyanine photosensitizer, 1.17, which triggered potent apoptotic events following
antisense treatment and photodynamic therapy of the resistant tumor cells [38]. Similarly,
combination approaches featuring the co-administration of an antisense oligonucleotide coupled
with potent anti-tumor agents have had the most success in translating gene therapy from pre-
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clinical to clinical applications. Combination of a Bcl-2 antisense oligonucleotide with potent
anti-cancer drugs doxorubicin, 1.18, and docetaxel, 1.19, were administered to patients with
locally advanced breast cancer in an extensive phase I/II clinical study [39]. Despite encouraging
initial results, pharmacodynamics indicated the antisense oligonucleotide displayed modest
oncogene knockdown effects, potentially related to the limited delivery at the localized tumor
site. Thus, extensive research has been dedicated to improve the cellular delivery of the antisense
oligonucleotides with an efficacy and selectivity that may trigger cell death exclusively in
cancer.

1.17

1.18

1.19

1.15

1.15

Figure 1.8. Potent anti-cancer drugs used in combination or conjugated to antisense
oligonucleotides [38,39].

The arginine-glycine-aspartic acid (RGD) tripeptide is a selective and high affinity
binding ligand for the vβ3 integrin receptors that are overexpressed and cell surface localized
on a variety of tumor cells types making them valid biomarkers for cancer-targeted delivery
approaches [40]. RGD peptide conjugates of the splice switching antisense oligonucleotides were
effectively administered in melanoma cells transplanted in mice xenografts [41]. Localized
expression of the luciferase gene at the tumor site was apparent by optical imaging of the
luciferin photon emission (Figure 1.9) following a 3 day incubation period with the RGD15

antisense oligonucleotide. This experiment underscores the significance of a cancer-targeting
vector in ushering the selective delivery of oligonucleotides at the targeted tumor site for
potential applications in cancer-targeting gene therapy. This was recently proven by combining
the cancer-targeting properties of RGD, with the oncogene silencing effects of the antisense
oligonucleotide

down-regulating

luteinizing

hormone

releasing

hormone

(LH-RH)

overexpression in H1299 lung cancer cells and/or xenografts in athymic nude BALB/c mice [42].

Figure 1.9. In vivo effects of RGD-antisense oligonucleotide (623). Localized site distribution of
RGD-623 is apparent following a 3 day incubation treatment in nude mice xenogratfs bearing
human A375 melanoma cells Figure adapted from reference Juliano, R.L.; Ming, X.; Nakagawa,
O. Acc. Chem. Res. 2012, 45, 1067-1076. (41).

The preparation of RGD-oligonucleotide conjugates is based on a series of bioorthogonal reactions which ligate the peptide and oligonucleotide by virtue of a reversible oxime
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(Scheme 1.2, a), a cyclic thiazolidine (Scheme 1.2, a) and a thioether linkage (Scheme 1.2, b)
[42].
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Scheme 1.2. Bioconjugation strategies for the preparation of RGD peptide-oligonucleotide
conjugates. Figure adapted from Sundaram, S.; Trivedi, R.; Durairaj, C.; Ramesh, R.; Ambati,
B.K.; Kompella, U.B. Clin. Cancer Res. 2009, 15, 7299-7308.
42.
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1.3.3

SYNTHESIS

AND

ANTI-CANCER

APPLICATIONS

OF

APTAMER

OLIGONUCLOETIDE BIOCONJUGATES
Drug resistance remains key obstacle for the successful treatment of metastatic cancers.
Combinations approaches are at forefront of treating MDR tumors. In a recent case study, the
selective conjugation of Doxorubicin (Dox) to a single site within a DNA hairpin results in a
highly stable complex (i.e. aptamer) that enables Dox to be used more effectively in MDR tumor
types [44]. Conjugation of Dox at a selective Gua 15 site within the loop domain of the DNA
hairpin was accomplished by reductive amination (Scheme 1.3) and confirmed by site-specific
labeling with [2-15N]-2′-deoxyguanosine followed by spectroscopic analyses using [1H−15N] 2D
NMR.

1.32
1.20
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1.15

1.33
1.20

1.18
1.15

1.34
1.20

1.35
1.20

1.18

1.18
1.15
1.15

Scheme 1.3. Reductive amination of Dox at localized Gua 12 and 15 on DNA hairpin, 1.26,
Sundaram, S.; Trivedi, R.; Durairaj, C.; Ramesh, R.; Ambati, B.K.; Kompella, U.B. Clin. Cancer
Res. 2009, 15, 7299-7308.
[44].

Moreover, this conjugate was characterized as a 1:1 stoichiometric complex according to
ESI-QTOF mass spectrometry, UV spectroscopy and computational analysis (Figure 1.10). This
stable complex ultimately results in a DOX-conjugated hairpin (DCH) with a half-life >30 h.
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This may translate into extended resident times of the drug at the localized tumor site leading to
a prolonged therapeutic response. The DCH complex was subsequently conjugated with folic
acid (FA) to increase internalization and activity within MDR breast cancer cells. Thus, this dual
bio-conjugate, DCH-FA, can be used for a safer and more effective administration of Dox and
additional anticancer drugs [44].

Figure 1.10. Structures and models of DCH. Dox is covalently bound to G12 and intercalated
between the G15:C11 and the A10:T16 base pairs. Coloring scheme for structures are designated
as follows: guanine, green; adenine, red; thymine, yellow; cytosine, blue; Dox, light blue;
methylene linker, white; DNA backbone, brown. (A-C) 3D structure of DCH. (D) 3D structure
of the unreacted hairpin. Figure adapted from reference 44.
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1.3.4 SYNTHESIS AND ANTI-CANCER APPLICATIONS OF SHORT-INTERFERING
RNA (siRNA) BIOCONJUGATES

The RNA interference (RNAi) mechanism for silencing oncogene expression in cancer
has also received special attention since the seminal works of Fire and Mello, dating back to
1998, produced a full understanding of the RNAi pathway in Caenorhabditis Elegans [45]. For
their contributions to the field, Fire and Mello were awarded the Nobel Prize in physiology or
medicine in 2006. The RNAi mechanism for down-regulating gene expression is a naturally
occurring process, that’s triggered when short (18-21 base pairs) double-stranded RNA, aptly
named short interfering RNA (siRNA), are delivered into cells causing sequence-specific gene
silencing effects (Figure 1.11). The accepted RNAi mechanism of action initially involves long,
double-stranded RNA (typically >200 nucleotides) that are cleaved by the RNA III protein Dicer
into short RNA duplexes (siRNA) in an ATP-dependent reaction [46]. Typically the siRNAs are
phosphorylated at their 5′-ends and have two unpaired nucleotides at the unphosphorylated 3′ends for recognition, binding and activation of the RNA-Induced Silencing Complex (RISC).
The siRNAs are assembled within RISC, a protein complex loaded with endoribonucleases such
as the Argonaute 2 protein, which catalyzes sequence specific RNA hydrolysis [47]. The sense
siRNA strand is hydrolyzed leaving behind the single-stranded antisense RNA (aRNA) which
directs RISC to a target messenger RNA (mRNA) sequence forming the aRNA:mRNA hybrid.
This ribonucleoprotein complex inhibits protein translation of the mRNA sequence. Moreover,
the aRNA:mRNA hybrid is a substrate for the processing activity of the Argonaute 2 enzyme,
which selectively hydrolyzes the mRNA strand and permanently silences mRNA expression.
Since the aRNA strand is left intact, the RNAi mechanism for silencing mRNA expression is a
catalytic process, resulting in potent effects with minimal quantities (pmol) of siRNA. Therefore,
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the RNAi technology has been applied for treating many human diseases associated with the
expression of malignant genes (e.g. metabolic disorders, cancer, gene mutations and deletions
etc.) [48]. In spite of its unlimited potential in gene therapy applications, siRNAs are limited by
poor pharmacokinetic properties which has hindered their translation from pre-clinical to clinical
use [49]. Therefore, synthetic siRNAs have been created and conjugated with functionality
which improves their ‘drug-like’ potential in treating genetic disorders in vivo [50].

Figure 1.11. The RNAi mechanism of action. Dicer cleaves double-stranded RNA producing
short siRNA duplexes. The RNA-induced silencing complex (RISC) binds to the siRNA
21

substrates and the Argonaute 2 endoribonuclease cleaves the sense siRNA strand. The siRNA is
unwound and the antisense siRNA strand directs the RISC to a target messenger RNA (mRNA),
resulting in the formation of the aRNA:mRNA hybrid. This hybrid inhibits mRNA translation
and triggers endonucleolytic cleavage of the mRNA strand. The mRNA is degraded, and the
gene silenced (Figure adapted from http://www.uni-konstanz.de/FuF/chemie/jhartig/).
siRNA-ligand conjugates have been effectively produced using the copper-catalyzed
azide-alkyne cycloaddition (CuAAC) or click reaction [51]. Nucleosides bearing 2’, 3’ or 5’alkyne groups were effectively conjugated with ligands bearing azido groups such as lipophilic
long chain alkyls, cholesterols, oligoamines and carbohydrates (Scheme 1.4). The conjugated
siRNAs effectively silenced luciferase gene activity in a transformed HeLa cell line, illustrating
their potential in RNAi applications.

Scheme 1.4. Click reaction of oligonucleotide alkynes with azido ligands to produce
bioconjugates, 1.43-1.48. Reaction and conditions: i. alkyne/azide/CuSO4 5H2O/TBTA/ sodium
ascorbate (1:3:0.4:3:3 mol ratio), H2O/MeOH/THF (1 mL, 2:2:1, v/v), 60 oC, microwave
radiation, 45 min, yields (89-99%). ii. 40% methylamine/H2O. Reaction scheme adapted from
reference 51.

Cell targeting ligands have also been conjugated to siRNA for cell specific gene silencing
effects. For example, di-, tri- and tetra-valent cyclic RGD peptides have been conjugated to
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siRNA targeting the firefly luciferase gene in V3 positive M21+ human melanoma cells [52].
In this bioconjugation reaction a reactive cysteinyl thiol was introduced within the peptide
sequence for Michael addition with a maleimide group at the 3’-end of the siRNA (Scheme 1.5).

1.49

1.50

1.20

1.20

1.18

1.18

1.15

1.15

1.51
1.20

1.18
1.15

Scheme 1.5. Michael addition of a trivalent cyclic RGD, 1.51, with a maleimide-derived siRNA,
1.49, to produce the bioconjugate, 1.50. Reaction and conditions: i. 0.4 M KCl, 40%
MeCN:H2O, room temperature, overnight reaction.
Recent advances in bioorthogonal chemistry have enabled the development of the first in
human clinical trials of an siRNA conjugate targeting the vascular endothelial growth factor
(VEGF) and the kinesin spindle protein (KSP) in liver metastases associated with endometrial
cancer [8]. The siRNA therapeutic is well tolerated and shows promising pharmacodynamics
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paving the way for the first siRNA oncogene therapeutic to reach the open market. The key to its
success is associated with the combination of siRNA and a lipid nanoparticle, (LNP), which
enables effective tumor penetration for RNAi activity (Figure 1.1). Thus, bioconjugation
methods are at the heart of developing effective nucleic acid therapeutics against tumors.

1.4 THESIS OBJECTIVES
Nucleic acid bioconjugates have gained widespread use in medicinal chemistry research
programs aimed at fighting human malignancies such as cancer, diabetes, genetic and infectious
diseases. Their popularity stems from the ability to accelerate the drug development process by
conjugating chemical functionality that may improve the pharmacology of the bioactive
nucleoside. Moreover, this strategy has been proven to be effective with small molecule
nucleoside analogs and those derived from lengthy oligonucleotide sequences. Considering these
fruitful applications, my thesis shows the synthesis, characterization and therapeutic potential of
novel classes of nucleic acid bioconjugates. These are based on (a) aminoacyl nucleolipids, from
which a simple, versatile and efficient synthesis strategy has been developed for this new class of
DNA binding molecules (Chapter 2). This nucleoside based bio-conjugate exhibited GRP78
oncogene binding affinity (KD: 0.25 mM) and selective anti-leukemic activity in a single dose
(10 µM) screen against a panel of 60 cancer cell lines [53]. Additionally, the (b) diacylhydrazinelinked dinucleosides, encompass a novel class of nucleic acid bioconjugates proposed to improve
the structural stability of turn conformations in DNA or RNA hairpin secondary structures. My
most recent advances in the synthesis, structure elucidation and biological evaluation of these
putative hairpin mimics will also be described in Chapter 3. Lastly, (c) the synthesis, biophysical properties and GRP78 DNA cleavage activity of a phthalocyanine-linked
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oligonucleotide bioconjugate will be highlighted for photodynamic oncogene therapy
applications in Chapter 4 [54]. Thus, this thesis will underscore my contributions to the
flourishing field of nucleic acid bioconjugation for potential anti-cancer applications.
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CHAPTER 2: SYNTHESIS, DNA BINDING AND ANTI-LEUKEMIC
ACTIVITY OF AN AMINOACYL NUCLEOLIPID
2.1 GENERAL INTRODUCTION
Aminoacyl nucleolipids encompass an interesting class of synthetic amphiphilic
bioconjugates, which own the ability to assemble into higher-ordered biomaterials for
applications in gene therapy, medicinal chemistry and biotechnology [1,2]. The self-assembly
properties of aminoacyl nucleolipids is partly related to its structure [3,4]. This includes a
nucleoside which contains a purine or pyrimidine nucleobase that may participate in H-bonding
interactions, an aminoacyl group that contains the potential for ionic bonding and lipids which
enable the self-assembly of these amphiphiles through non-polar interactions (Figure 2.2). For
example, the synthetic guanosine aminoacyl nucleoplipids (Figure 2.1, 2.1, 2.2) displayed the
ability to form stable G-tetraplexes (G-tetrads) in organic solvents [5], were also found to behave
as organometallic chelators with Li+ and K+ ions and displayed the ability to transport H+/OHions in the presence of an externally applied pH gradient [3]. Moreover, aminoacyl nucleolipids,
2.1 and 2.2 showed moderate to weak activity (IC50: 17 - >103 µM) in an anti-proliferative assay
across a panel of 5 tumor cell lines underscoring their potential in biomedical applications [3]. In
a related case study, a cationic aminoacyl surfactant (Figure 2.1, 2.3) demonstrated micelle
forming capabilities in water according to DLS studies and modest cell toxicities (IC50: 19 – 98
µM) relative to the cytotoxic cetyl triethylammonium bromide (CTAB) cationic amphiphile in a
panel of human, rat and murine cell lines [4]. Interestingly, the biological activity of the
aminoacyl nucleolipid, 2.3, was found to occur at concentrations nearing its critical micelle
concentration (cmc: 40 µM), highlighting its structure-activity relationship. In light of their
abilities to form stable and relatively benign cationic assemblies, aminoacyl nucleolipids have
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been applied to gene delivery applications in cell-based studies [6,7].

The rise of short

interfering RNAs (siRNAs) has enabled the widespread application of silencing detrimental
mRNA expression through the RNA interference (RNAi) pathway [8]. In spite of its unlimited
potential in gene therapy applications, siRNAs are plagued by poor cell permeability which
limits their therapeutic efficacy. In an effort to overcome this challenge, siRNA delivery agents
(transfection agents) have been formulated to effectively condense and deliver siRNA across the
amphiphilic cell membrane for RNAi activity. In this scope, a small library of synthetic
polycationic nucleolipids have been formulated for siRNA packaging and transfection within a
HeLa cell line for potent suppression of Vascular Endothelial Growth Factor (VEGF) expression
[6]. The spermine derived aminoacyl nucleolipid (Figure 2.1, 2.4) exhibited comparable siRNA
transfection efficiencies (>90% VEGF knockdown) and cell death (~20%) as the benchmark
Lipofectamine-based siRNA transfections. Moreover, metabolically stable variants of aminoacyl
nucleolipids have also been formulated for siRNA delivery applications in HeLa cells [7]. For
example, an arginine-linked nucleolipid (Figure 2.1, 2.5) has been synthesized by virtue of a
1,3-dipolar cycloaddition to generate a stable triazole linkage in between the aminoacyl group
and the nucleolipid, whereas the lipid groups were installed using carbamate linkages. This
cationic nucleolipid formed stable complexes with anti-VEGF siRNA as discerned from gel shift
binding assays and DLS experiments, while facilitating siRNA transfection for potent VEGF
knockdown (>90%) which also paralleled the effects of the Lipofectamine-based siRNA
transfections in HeLa cells [7]. These examples effectively demonstrate the fruitful
implementation of aminoacyl nucleolipids in condensing oligonucleotides for medicinal
chemistry applications.
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Figure 2.1 Structures of synthetic aminoacyl nucleolipids [3-7].

2.2 CHAPTER OBJECTIVES
Inspired by their versatility and utility in bio-medical applications, this thesis chapter
aims to design, develop and apply aminoacyl nucleolipids to anti-cancer therapy. In this study,
an aminoacyl nucleolipid was designed to contain an ionizable ammonium group that can
participate in ionic binding interactions (Figure 2.2) with the target promoter sequence of the
GRP78 oncogene. Moreover, the nucleolipid scaffold was also rationalized to exhibit favorable
amphiphilic properties (Figure 2.2) that may translate to effective anti-cancer activities in
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tumors. The synthesis strategy developed in collaboration with Emi Hanawa (Ph.D. student) in
the laboratory of Dr. Cecilia Marzabadi (Department of Chemistry, Seton Hall University)
enabled the chemical modification of guanosine with a carboxylic acid group at the 5’-position in
order to attach various bioactive modalities, one of which contained the desired aminoacyl
functionality. Moreover, the 2’ and 3’-hydroxyl groups of the nucleoside were used for the
attachment of the fatty acids, in order to produce the amphiphilic aminoacyl nucleolipid. It was
then characterized for its ability to bind to GRP78 DNA using Circular Dichroism (CD)
Spectroscopy, UV-Vis thermal denaturation and gel shift assays. In collaboration with Reeta
Yadav (Ph.D. student) in the laboratory of Dr. Uri Samuni (Department of Chemistry, Queen’s
College) the sizes of the complexes formed in between the aminoacyl nucleolipid and the
oncogene sequence was also characterized by Dynamic Light Scattering (DLS). Following
synthesis and characterization, the anti-cancer activity of the aminoacyl nucleolipid was
evaluated by the National Cancer Institute’s (NCI’s) 60 Cancer Cell Line Screen. Taken
together, this study highlights the rational design, synthesis, oncogene binding and anti-cancer
activity of a new representative of the aminoacyl nucleolipids. They encompass a relatively new
class of cationic amphiphilic conjugates whose structure, biophysical and biological properties
remain largely un-explored. In this chapter, we describe the synthesis, characterization and
medicinal chemistry applications of an aminoacyl nucleolipid (Figure 2.2). This study forms the
basis for the development of new chemistries that may empower the combinatorial library
synthesis of aminoacyl nucleolipids for exploring structure-activity relationships with biological
targets in cancer.
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Figure 2.2. Chemical structure and DNA-binding interactions of aminoacyl nucleolipid, 2.6.
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2.3 SYNTHESIS, DNA BINDING AND ANTI-LEUKEMIC ACTIVITY OF AN
AMINOACYL NUCLEOLOPID
Pradeepkumar
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Figure 2.3. Graphical abstract describing the binding of an aminoacyl nucleolipid bioconjugate
to the oncogene GRP78 DNA sequence. Figure adapted from Patel, P.; Hanawa, E.; Yadav, R.;
Samuni, U.; Marzabadi, C.; Sabatino, D. Bioorg. Med. Chem. Lett. 2013, 23, 5086-5090 [9].
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2.3.1 ABSTRACT
The synthesis and characterization of a new class of DNA binding molecules exhibiting
potent and selective anti-leukemic activity is described. The synthesis of an aminoacyl
nucleolipid was developed from an efficient EEDQ coupling strategy, in which a series of seven
bioconjugates were synthesized in yields of 53-78%. Guanosine bioconjugate 2.13, was used as
building block for the synthesis of a target aminoacyl nucleolipid 2.6. Its GRP78 DNA binding
affinity was confirmed by gel shift assay, CD spectroscopy, Tm measurements and dynamic light
scattering experiments. Moreover, in a single dose (10 µM) screen against a panel of 60 cancer
cell lines, aminoacyl nucleolipid 2.6 was found to selectively trigger greater than 90% cell death
in a SR human leukemia cancer cell line. The reported aminoacyl nucleolipid represents a useful
model for a new class of DNA binding molecules for the development of potent and selective
anti-cancer agents.

2.3.2 INTRODUCTION
Aminoacyl nucleolipids represent an interesting class of bioconjugates owning the ability to
form stable, higher-ordered structures for potential applications in medicinal chemistry [14,6,7,9]. For example, they form complexes with short-interfering RNA (siRNA), applicable in
siRNA transfection leading to the down-regulation of mRNA and protein expression in cancer
cells [6,7].
Aminoacyl nucleolipids may also own the ability to bind and stabilize double-stranded DNA by
a series of non-covalent interactions. These include, H-bond base-pairing and π-stacking of the
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nucleoside base as seen in the canonical Watson-Crick [10a] and Hoogsteen base-pairing
interactions of ligand with duplex DNA [10b,10c]. The ionic interactions between the positively
charged aminoacyl and the anionic phosphodiester DNA backbone as described in the
condensation of DNA with poly-Arg and poly-Lys sequences [11]. Lastly, the van der
Waals/hydrophobic interactions of the lipids create an amphiphilic microenvironment for DNA
complex formation and cell permeability [12] (Figure 2.2). In the fight against cancer, stable
DNA-bioconjugate interactions may form the basis for an effective gene therapy strategy [13].
The Glucose-regulated protein 78 (GRP78) is a chaperone protein that functions to regulate
protein folding events in the lumen of the endoplasmic reticulum (ER) of all cell types [14]. In
cancer, GRP78 is overexpressed and exclusively localized on the cell surface where it exhibits a
variety of signal transduction pathways associated with tumorigenesis and resistance towards
apoptosis [15]. Thus, GRP78 functions as an ideal molecular marker for the selective detection
and treatment of cancer cells [16]. In an effort to develop potent GRP78 DNA binders for anticancer applications, we describe the development of an aminoacyl nucleolipid, 2.6. This
aminoacyl nucleolipid has been validated by its ability to bind to the promoter region of GRP78
DNA, while soliciting potent and selective anti-leukemic activity.
2.3.3 RESULTS AND DISCUSSION
2.3.4 SYNTHESIS OF AN AMINOACYL NUCLEOLIPID
The synthetic strategy begins with the generation of N-isobutyryl 5’-carboxy 2’,3’-bis-O(carbobenzyloxy) guanosine, 2.10, (Scheme 2.1) as the building block component for furnishing
bioconjugates (Table 2.1). In the preparation of 2.10, N-isobutyryl 5’-dimethoxytrityl guanosine,
2.7, was used as commercially available starting material to initiate the synthesis strategy. The
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Cbz protecting groups were installed using an excess of benzylchloroformate and DMAP in
DCM [17]. Following carbomylation, 2.8, was detritylated in 98% yield using 3% trichloroacetic
acid in DCM [18]. N-isobutyryl-2’,3’-bis-O-(carbobenzyloxy)guanosine, 2.9, was then oxidized
in 82% yield to the corresponding carboxylic acid, 2.10, using a TEMPO oxidation [19].

Scheme 2.1. Synthesis of N-isobutyryl 5’-carboxy 2’,3’-bis-O-(carbobenzyloxy) guanosine,
2.10. Conditions: (a) DMAP, benzyl chloroformate, DCM, 0 oC then r.t., 72 h, 77%, (b) 3%
TCA:DCM, r.t., 15 min, 98%, (c) TEMPO, BAIB, MeCN:H2O (50:50 v/v), r.t., 15 h, 82%.

With building block 2.10 in hand, a small library of aminoacyl and lipid conjugates were
prepared. Coupling conditions were optimized based on literature precedence [20], by using Nethoxycarbonyl 1,2-ethoxy-1,2-dihydroquinoline, EEDQ, (2 equiv) as coupling reagent and N,N36

diisopropylethylamine, DIEA (2 equiv) as the base in DMF. Briefly, alkyl amines or alcohols
(Table 2.1, entries 2.11, 2.12, 2.17) were coupled with 2.10 to their corresponding amides or
esters, respectively, in yields of 55-73%. In similar fashion, amino esters (Table 2.1, entries
2.13- 2.16) were coupled to their corresponding amides with building block 2.10 in yields
ranging from 53-78%. The pure bioconjugates were characterized by NMR, IR, MS and
polarimetry.

Table 2.1. Bioconjugation of aminoacyl and lipid nucleosides.
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Bioconjugate 2.13, was selected for the preparation of aminoacyl nucleolipid, 2.6,
following a simple three-step procedure. Firstly, the Cbz protecting groups were removed using
conventional hydrogenation conditions [17], generating diol 2.18 in quantitative yields. The
product was then dissolved in pyridine and acylated with an excess of palmitoyl chloride [21] to
afford the protected aminoacyl nucleolipid 2.19 in >99% yield. Following purification, the Bocprotecting group of 2.19 was removed using 50% TFA:DCM, followed by salt exchange with
aqueous HCl. The desired product, 2.6, obtained in quantitative yield was lyophilized to dryness
and characterized (Scheme 2.2).

Scheme 2.2. Synthesis of aminoacyl nucleolipid, 2.6. Conditions: (a) H2, 10% Pd/C, EtOH, r.t.,
1.5 h, >99% (b) palmitoyl chloride, DMAP, pyr., 2 h, >99% (c) 50% TFA:DCM, 2 h, r.t., then 1
M HCl, 3 h, >99%.
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Attempts to selectively deprotect the guanine NH-i-Bu using mildly basic conditions [22]
resulted in concomitant ester cleavage of the palmitoyls and methyl ester groups. Thus, we
rationalized that partial protection of aminoacyl nucleolipid, 2.6 may confer greater resistance
towards degradation, while inhibiting formation of higher-order self-assemblies (i.e. guaninetetraplexes) that may influence DNA binding and biological activity [3]. CD spectroscopy of
aminoacyl nucleolipid 2.6 (0.2-3.9 mM) did not exhibit a guanine-tetraplex structure at higher
concentrations (0.9-3.9 mM) (Figure 2.4). They are usually characterized by an intense positive
band near 264 nm and a negative one near 245 nm (for parallel tetraplex structures), and a
positive band near 290 nm and negative ones near 260 and 245 nm (for anti-parallel tetraplex
structures) [23].

Figure 2.4. CD spectrum of 2.6 (0.2-3.9 mM) in phosphate buffer at 25 oC.
2.3.5 DNA BINDING STUDIES OF AMINOACYL NUCLEOLPID 2.6
The promoter region of GRP78 DNA encompassing nucleotides 252-269 [24] was synthesized
by conventional automated solid-phase oligonucleotide synthesis [25]. The oligonucleotides
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were purified by reverse-phase ion-pairing HPLC (RP-IP HPLC) [26] and characterized by mass
spectrometry (Figure 2.5).

Figure 2.5. HPLC chromatograms (260 nm) and corresponding mass spectra data of GRP78
DNA (A) sense (ss) and (B) antisense (as) strands
Complementary sequences (0.57 µM) were annealed in 15 μL of 30% sucrose in 5x TAE
buffer (89 mM Tris/acetate, 2.5 mM EDTA, pH = 4.2) and incubated at 37 oC for 36 h with and
without ligand 2.6, at 0, 5, 25, 50, and 100 equiv, based on the ratio of 2.6/DNA phosphate
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groups, which corresponds to the following concentrations: 0, 0.2, 0.9, 1.9, 3.9 mM, respectively.
A 24% native PAGE gel shift binding assay was performed to evaluate ligand binding to GRP78
DNA (Figure 2.6). Following electrophoresis, gradual disappearance of the DNA bands was
visualized by UV-shadowing at 260 nm. The observed trend is typical of higher-order complex
structures, which results in the diminished intensity of the UV-bands corresponding to duplex
DNA [27]. Quantitative analysis of the ratio between duplex DNA with and without 2.6
demonstrated 50% duplex binding affinity (KD) at 0.7 mM.

Figure 2.6. Gel shift assay for GRP78 DNA with 2.6: From lane 3 to 7, increasing amount of
ligand 2.6 from 0 to 100 equiv. 2.6/P (0-3.9 mM). Lane 1 and 2 are single stranded GRP78 DNA

The GRP78 DNA binding stability with and without 2.6 was evaluated by thermal
denaturation (Figure 2.7). Changes in duplex DNA UV-absorption at 260 nm was monitored
with increasing temperatures (5-90 oC). DNA samples (1.1 µM) were prepared by annealing
complementary single strands in physiological phosphate binding buffer (140 mM KCl, 1 mM
MgCl2, 5 mM Na2PHO4 adjusted to pH 7.2). The melting temperature (Tm) of native GRP78
DNA was evaluated at 66 oC, whereas the addition of ligand (0.2-3.9 mM) produced drastic
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changes in the DNA melting curves. For example, at 0.2 mM, 2.6 exhibited a stabilizing effect
on GRP78 DNA duplex (ΔTm = +4 oC), whereas at higher concentrations (0.9-3.9 mM) changes
in duplex DNA hyperchromicities with increasing temperatures were indicative of higher-order
structure transitions [28].

Figure 2.7. Thermal denaturation curves. Changes in % hyperchromicity at 260 nm versus
temperature of GRP78 DNA (1.1 µM) in the presence of ligand 2.6 (0.2-3.9 mM).

In order to gain greater insight into the structural changes of native GRP78 DNA with the
addition of ligand 2.6, the Circular Dichroism (CD) spectrum was collected (Figure 2.8). The
samples were prepared as previously described for the thermal denaturation studies. The native
GRP78 DNA duplex exhibited a CD structure consistent with a B-type helix, with characteristic
broad maximum band between 260 - 280 nm and a minimum at 248 nm [29]. The amplitudes of
the molar ellipticities at these characteristic wavelengths were found to diminish upon titration
with 2.6 (0.2-3.9 mM) suggesting that the ligand-bound structure compromises DNA duplex
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helicity until the formation of a higher-order complex persists at higher ligand concentrations
(i.e. 100 equiv 2.6/P, 3.9 mM).

Figure 2.8 Circular Dichorism (CD) spectrum of GRP78 DNA (1.1 µM) with complexing ligand
2.6 (0-3.9 mM) in phosphate buffer.

To further characterize the size of the complex formed between GRP78 DNA and 2.6,
dynamic light scattering (DLS) studies were performed relative to native DNA and aminoacyl
nucleolipid, 2.6. DNA (1.1 µM) was prepared with and without aminoacyl nucleolipid 2.6 (3.9
mM) and incubated in phosphate buffer for 36 hours prior to DLS measurements (Table 2.2).
The observed hydrodynamic radii (Rh) for the particles shows fixed values for DNA (0.9 nm)
and aminoacyl nucleolipid 2.6 (~460 nm). Alternatively, the complex formed in between DNA
and 2.6 illustrates a 3.4 fold increase in particle size, suggesting the formation of a higher-order
complex structure.
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Table 2.2 Hydrodynamic Radii (Rh, nm) of aminoacyl nucleolipid, 2.6, and DNA+2.6 at 25 oC.
Compound

2.6

DNA+2.6

Time

Rh

(h)

(nm)

0

468±1.9

36

460±1.2

0

2707±11

36

9294±53

2.3.6 ANTI-CANCER ACTIVITY OF AMINOACYL NUCLEOLIPID 2.6
In order to assess the anti-cancer activity of aminoacyl nucleolipid 2.6, a cancer cell line
screening assay was conducted against a panel of 60 cell lines selected at the National Cancer
Institute (NCI) [30]. A single dose (10 µM) screen was performed with 2.6, and cell viability was
determined following 48 h incubation with cancer cells at 37 oC. A sulforhodamine B (SRB cell
viability assay [31] was performed to determine cell death in the presence of 2.6. Aminoacyl
nucleolipid 2.6 was found to exhibit potent and selective anti-cancer activity (see Supporting
Information, Figure 2.10), with greater than 90% cell death against a SR human lymphoblastic
leukemia cancer cell line (Figure 2.9). Interestingly, GRP78 expression levels are elevated in
leukemic blasts of adult patients and in early relapse childhood leukemia [32] suggesting a
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correlation between the GRP78 DNA binding affinity and anti-leukemic activity of aminoacyl
nucleolipid 2.6. We are currently investigating the bio-molecular basis for the potent and
selective activity of 2.6 in leukemia cells.

Figure 2.9. Cell death of human leukemia cell lines following treatment with 2.6 (10 µM) for 48
h.
2.3.7 CONCLUSIONS
In conclusion, with the synthesis of derivative 2.6, we have demonstrated the utility of a
new class of aminoacyl nucleolipid, which can have great relevance due to their tight binding
with GRP78 DNA and marked ability to trigger potent and selective anti-leukemic activity. This
work paves the way for additional studies into the mechanism of aminoacyl nucleolipid anticancer activity. Moreover, 2.6 may form the basis for novel ligand design and development for
anti-cancer applications.
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2.3.8 EXPERIMENTAL SECTION
General Methods. All non-aqueous reactions were performed under inert atmosphere (nitrogen)
unless specified. All glassware was dried and stored in a pre-heated oven (160 oC) and cooled
under inert atmosphere prior to use. Anhydrous solvents and reagents were purchased from
Aldrich (St. Louis, MO) and used as received. Analytical thin-layer chromatography (TLC) was
performed on aluminum-backed silica gel plates (Merck 60 F254). TLCs were visualized under
UV shadowing (260 nm) or staining (10% H2SO4/MeOH). Compound purification using silica
gel chromatography was performed on a 230-400 mesh silica (Sorbent Technologies). Melting
points were obtained on a Thermo Melt apparatus. Specific rotations measurements were
recorded on a DigiPol 781 Automatic Polarimeter (Rudolph Instruments, Fairfield, NJ, USA)
and collected as averages of five measurements per compound. Data are reported as follows: [α]λ
temp, concentration (c in g/100 mL), in Ace, MeOH, DCM or CHCl3. Molecular weights were
measured as direct injections on a Hewlett Packard series 1100 MSD equipped with ESI as ionsource in positive mode using 50/50 v/v MeOH/H2O at a flow-rate of 1 mL/min. Infrared (IR)
spectra were obtained on a Nicolet 4700 FT-IR (ThermoElectron Co.) coupled with OMNIC
software (driver version: 7.1). The compounds were deposited on a KBr plate with cast film
technique and the data was collected as an average of 3 scans in wavenumbers (cm-1). Nuclear
magnetic resonance spectra (1H, 13C, COSY NMR) were recorded on an OXFORD NMR AS500
spectrophotometer. The NMR spectra were obtained at ambient temperature using an indirect
pulse-field gradient (ID-PFG) probe. The obtained data was processed using VNMRJ software
(version 2.2). The 1H and 13C assignments were based on gCOSY and gHMQC NMR correlation
experiments.
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Synthesis.
N-Isobutyryl-5’-O-(4-dimethoxytrityl)-2’,3’-di-O-(carbobenzyloxy) guanosine (2.8): NIsobutyryl-5’-O-(4-dimethoxytrityl) guanosine (3.0 g, 4.5 mmol) was suspended in
dichloromethane (90 mL) and DMAP (8.2 g, 67 mmol) was added. After cooling to 0 ºC, benzyl
chloroformate (5.4 mL, 38 mmol) was added dropwise and the suspension was stirred at room
temperature. After 3 days, the solution was diluted with dichloromethane and evaporated to a
viscous oil. The product was purified by silica gel chromatography (Ace/DCM 9:1) giving
nucleoside 2.8 (3.2 g, 3.9 mmol) as a white solid. Yield : 78%. m.p. 131 ºC. TLC (Ace/DCM
9:1) Rf: 0.8. [ ]

-29 (c 0.005, DCM). IR (KBr) υmax (cm-1) = 3160, 3009, 2917, 2837, 1759,

1674, 1608, 1564, 1508, 1463, 1408, 1381, 1275, 1252, 1177, 1155, 1094, 1033, 904, 829, 755.
1

H NMR (500 MHz, DMSO-d6): δ 8.09 (s, 1H, H8), 6.79-7.36 (m, 23H, arom. DMT, Cbz), 6.13

(d, J = 7 Hz, 1H, 1H’), 5.94 (t, J = 6 Hz, 1H, 2H’), 5.46 (dd, J = 3, 6 Hz, 1H, H3’), 5.13 (d, J = 5
Hz, 2H, CH2), 5.10 (d, J = 2 Hz, 2H, CH2), 4.33 (m, 1H, H4’), 3.71 (s, 6H, 2xOCH3), 3.49 (dd, J
= 6, 10 Hz, 1H, 5H’), 3.28 (dd, J = 5, 10 Hz, 1H, H5’’), 2.68 (m, 1H, i-BuH), 1.1 (d, J = 1 Hz,
3H, i-BuCH3), 1.09 (d, J = 1Hz, 3H, i-BuCH3). 13C NMR (126 MHz, DMSO-d6) δ: 178.3, 158.8,
155.4, 154.2, 153.7, 148.1, 147.2, 144.6, 139.2, 135.9, 135.4, 134.5, 130.0, 130.02, 129.1, 128.8,
128.7, 128.6, 128.5, 128.5, 128.4, 128.1, 128.0, 127.8, 127.8, 127.2, 122.5, 113.3, 113.2, 113.1,
86.43, 85.03, 81.40, 77.31, 77.05, 76.80, 74.60, 74.13, 70.56, 70.34, 62.64, 55.23, 35.99, 18.95,
18.44. ESI MS (m/z) calculated for C51H48N5O12 [M-H], 922.3; found 922.6.
N-Isobutyryl-2’,3’-di-O-(carbobenzyloxy) guanosine (2.9): To compound 2.8 (3.0 g, 3.2
mmol), 3% trichloroacetic acid in dichloromethane (50 mL) was added at room temperature. The
reaction reached completion in 15 minutes as detected by TLC. The product was extracted with
DCM (10 mL) and washed with 5% NaHCO3 (10 mL). The organic layer was dried over Na2SO4
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and concentrated in vacuo to afford a dark yellow crude residue. The crude product was purified
by a flash silica gel column chromatography (Ace/DCM 1:3) giving nucleoside 2.9 (2 g, 3.2
mmol) as a white solid. Yield : 98%, TLC (Ace/DCM 1:3) Rf : 0.23. m.p. 98 ºC. [ ]

: 42.6 (c

0.005, DCM). IR (KBr) υmax (cm-1) = 3363, 3204, 2974, 1755, 1677, 1605, 1568, 1457, 1384,
1277, 1156, 1100, 1012, 949, 904, 831, 783, 754. 1H NMR (500 MHz, DMSO-d6): δ 12.07 (s,
1H, NH), 11.61 (s, 1H, NH), 8.3 (s, 1H, H8), 7.2-7.4 (m, 10H, arom. Cbz), 6.06 (d, J = 7 Hz, 1H,
1H’), 5.72 (dd, J = 5, 7.5 Hz, 1H, 2H’), 5.47 (t, J = 5 Hz, 1H, 3H’), 5.42 (t, J = 5 Hz, 1H, 4H’),
5.14 (d, J = 11 Hz, 2H, CH2), 5.07 (d, J = 2 Hz, 2H, CH2), 4.3 (brs, 1H, OH), 3.7 (dd, J = 5, 10
Hz, 2H, H5’, H5’’), 2.69 (m, 1H, i-BuH), 1.09 (d, J = 6, 7 Hz, 6H, i-BuCH3).

13

C NMR (126

MHz, DMSO-d6): δ 155.1, 153.9, 153.4, 137.6, 135.4, 135.2, 129.1, 129.0, 128.9, 128.8, 128.7,
123.1, 120.3, 83.89, 83.49, 76.90, 75.72, 70.31, 70.10, 61.25, 35.27, 19.29, 19.23. ESI MS (m/z),
calculated for C30H30N5O10, [M-H], 620.2; found 620.7.
N-Isobutyryl-5’-carboxy -2’,3’-di-O-(carbobenzyloxy) guanosine (2.10): N-Isobutyryl-2’,3’di-O-(carbobenzyloxy)

guanosine,

2.9,

(0.25

g,

0.4

mmol),

2,2,6,6-tetramethyl-1-

piperidinyloxy free radical (TEMPO) (15.6 mg, 1 mmol) and bis(acetoxy)iodobenzene (BAIB)
(258 mg, 8 mmol) were combined in a mixture of MeCN/H2O (1:1 v/v, 20 mL) and stirred
overnight at 25 ºC. Acetone (5 mL) was added followed by Et2O (25 mL) and the mixture was
stirred for an additional 2 h for completion as detected by TLC. The crude product, 2.10, was
filtered and washed with Et2O (10 mL) resulting in a yellow solid (0.21 g, 0.33 mmol). Yield:
82%, TLC (MeOH/DCM 1:9) Rf :0.25. m.p. >240 ºC. [ ]

:-39 (c 0.005, DCM). IR (KBr) υmax

(cm-1) = 3499, 3411, 2996, 2914, 1660, 1438, 1403, 1311, 950, 928, 894, 666.

1

H NMR (500

MHz, DMSO-d6): δ 8.96 (s, 1H, H8 ), 7.2-7.4 (m, 10H arom. Cbz), 6.12 (d, J = 10 Hz, 1H,
1H’), 5.61 (t, J = 4 Hz, 1H, 2H’), 5.51 (d, J = 4, 1H, 3H’), 5.0-5.2 (m, 4H, CH2Cbz), 4.4 (s, 1H,
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4H’), 2.68 (m, 1H, i-BuH), 1.07 (d, J = 7 Hz, 6H, i-BuCH3). 13C NMR (DMSO-d6 ,126 MHz): δ
180.5, 171.1, 155.2, 154.0, 153.4, 149.4, 148.8, 139.3, 135.4, 135.2, 129.1, 129.0, 128.9, 128.9,
128.8, 128.7, 128.6, 128.6, 120.0, 84.03, 83.58, 79.63, 78.76, 70.30, 70.09, 69.81, 35.23, 19.51,
19.30, 19.20. ESI MS (m/z); Calculated for C30H30N5O11, [M+H], 636.19; found 636.4.
General procedure for the preparation of bio-conjugates (2.11-2.17) :
To a solution of 2.10 (50 mg, 0.08 mmol, 1 equiv) in DMF (2 mL), N-ethoxycarbonyl-2ethoxy-1,2-dihydroquinoline (EEDQ) (39.6 mg, 0.16 mmol, 2 equiv.) was added and the mixture
was stirred for 10 minutes at room temperature. N,N-Diisopropylethylamine (DIEA) (20.7 mg,
0.16 mmol, 2 equiv) was added to the reaction at room temperature. In a separate flask, alkyl
amine or alcohol (0.12 mmol, 1.5 equiv) was dissolved in DMF (2 mL) and added to the reaction
mixture. The reaction was then heated to 60 oC and continued for 12 hours. The reaction progress
was monitored by TLC until completion. The product was extracted in DCM (10 mL) and
washed with H2O (3 x 10 mL) and brine (10 mL). The organic layer was dried with Na2SO4,
filtered and concentrated in vacuo prior to purification by silica gel column chromatography.
N-Isobutyryl-5’-octanoyl-2’,3’-di-O-(carbobenzyloxy) guanosine (2.11).Yield: 73%; light
brown powder; m.p.= 72-74 oC; TLC (DCM:MeOH 95: 5): Rf = 0.62; [ ]

-8.2 (c 1.0,

acetone); IR (KBr) υmax (cm-1) = 2923, 2852, 1759, 1679, 1635, 1611, 1564, 1465, 1386, 1275,
1154, 1097, 1027, 971, 783, 754; 1H NMR (acetone-d6, 500 MHz): δ 12.04 (s, 1H), 10.43 (s,
1H), 8.27 (s, 1H), 7.47-7.34 (m, 10H), 6.21 (d, J = 5.9 Hz, 1H), 5.84 (m, 2H), 5.62 (s, 2H), 5.26
(dd, J = 9.3, 20 Hz, 2H), 5.11 (dd, J = 4.4, 17.5 Hz, 2H), 4.94 (s, 1H), 4.27 (t, J = 6.3 Hz, 2H),
2.89 (dt, J = 6.8, 13.7 Hz, 1H), 2.09 (s, 3H), 1.71-1.68 (m, 2H), 1.24 (d, J = 7 Hz, 6H), 0.88 (t, J
= 6.3 Hz, 8H);

13

C NMR (acetone-d6, 126 MHz): δ 216.3, 210, 172.2, 170.2, 164, 155.4, 155,
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138.6, 136.8, 130.3, 130.2, 118.7, 110.6, 86.3, 82.1, 78.2, 77.9, 72.0, 67.8, 61.7, 37.4, 33.3, 27.3,
24.1, 20.1, 15.1, 10.9; ESI MS (m/z) calculated for C38H44N5O11, [M-H]+, 746.8; found 746.8.

N-Isobutyryl-5’-diethyleneglycol-monoethyl-ether-2’,3’- di-O-(carbobenzyloxy) guanosine
(2.12).Yield: 55%; brown viscous liquid; TLC (DCM:MeOH 95:5): Rf = 0.62; [ ]

-70.2 (c

0.2, acetone); IR (KBr) υmax (cm-1) = 3138, 2928, 1753, 1691, 1238, 1126, 947, 784, 755; 1H
NMR (acetone-d6, 500 MHz): δ 11.97 (s, 1H), 10.52 (s, 1H), 8.02 (s, 1H), 7.47-7.34 (m, 10H),
6.64 (d, J = 2.5 Hz, 1H), 6.42 (t, J = 2.6 Hz, 1H), 6.24 (d, J = 2.5 Hz, 1H), 5.85 (m, 1H), 5.26
(dd, J = 5, 9 Hz, 2H), 5.14 (dd, J = 1.5, 8.5 Hz, 2H), 4.96 (s, 1H), 4.47 (m, 1H), 3.79-3.41 (m,
8H), 2.90 (q, J = 5 Hz, 1H), 1.27 (d, J = 25 Hz, 6H), 1.18 (t, J = 6.8 Hz, 3H);

13

C NMR

(acetone-d6, 126 MHz): δ181.5, 169.7, 160.3, 156.2, 155.3, 153.4, 150.3, 149.9, 138.9, 138.6,
136.6, 130.1, 130.0, 129.9, 122.8, 109.1, 90.6, 85.9, 84.8, 82.0, 78.0, 71.9, 71.8, 71.4, 71.2, 66.7,
65.4, 53.5, 39.3, 37.1, 19.9, 19.8, 16.1; ESI MS (m/z) calculated for C36H41N5O13, [M+] 751.7;
found 752.3.
N-Isobutyryl-5’-N-Boc-L-Lys(OMe)-2’,3’-di-O-(carbobenzyloxy) guanosine (2.13). Yield:
53%; yellowish brown powder; m.p.= 46-48 oC; TLC (DCM:MeOH 95:5): Rf = 0.61; [ ]

-

41.8 (c 1.0, acetone); IR (KBr) υmax (cm-1) = 3205, 3036, 2975, 1758, 1678, 1273, 1090, 1026,
901, 783; 1H NMR (acetone-d6, 500 MHz): δ 11.96 (s, 1H), 10.53 (s, 1H), 8.37 (s, 1H), 8.00-7.97
(m, 2H), 7.44-7.33 (m, 10H), 6.22 (d, J = 7.5 Hz, 1H), 5.96 (d, J = 2.5 Hz, 1H), 5.75 (dd, J = 1.9,
4.9 Hz, 1H), 5.26 (dd, J = 12.5, 24.5 Hz, 2H), 5.15 (dd, J = 12.2, 25.1 Hz, 2H), 4.91 (d, J = 2
Hz, 1H), 4.50-4.46 (m, 1H), 3.05-3.01 (m, 2H), 2.94 (s, 3H), 2.89 (q, J = 6.8 Hz, 1H), 1.89-1.74
(m, 2H), 1.49-1.45 (m, 2H), 1.40-1.39 (m, 2H), 1.38 (s, 9H), 1.24 (d, J = 6.9 Hz, 6H) ; 13C NMR
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(acetone-d6, 126 MHz): δ 180.9, 172.8, 169.0, 162.8, 156.8, 155.7, 154.8, 154.3, 149.9, 149.7,
138.6, 136.3, 136.1, 129.6, 129.5, 121.9, 85.6, 85.2, 82.2, 78.5, 77.5, 77.4, 71.2, 71.1, 53.7, 52.6,
52.2, 40.8, 36.7, 36.2, 31.8, 30.39, 23.76, 19.44, 19.32; ESI MS (m/z) calculated for
C42H51N7O14, [M+] 877.9; found 878.3.
N-Isobutyryl-5’-L-Phe(OMe)-2’,3’-di-O-(carbobenzyloxy) guanosine (2.14).Yield: 78%; light
brown powder; m.p.= 73 oC; TLC (DCM:MeOH 95:5): Rf = 0.62; [ ]

-4.94 (c 0.1, acetone);

IR (KBr) υmax (cm-1) = 3188, 2927, 1754, 1683, 1275, 1083, 783; 1H NMR (acetone-d6, 500
MHz): δ 12.07 (s, 1H), 10.43 (s, 1H), 8.12 (s, 1H), 7.84 (d, J = 7.8 Hz, 1H), 7.45-7.30 (m, 10H),
7.25-7.16 (m, 5H), 6.19 (d, J = 7.3 Hz, 1H), 5.86 (dd, J = 4.9, 7.3 Hz, 1H), 5.72 (dd, J = 1.7, 4.6
Hz, 1H), 5.21 (dd, J = 11.1, 25 Hz, 2H), 5.12 (dd, J = 12, 25 Hz, 2H), 4.85 (d, J = 1.5 Hz, 1H),
4.82-4.76 (m, 1H), 3.70 (s, 3H), 3.20 (d, J = 6.3 Hz, 1H), 3.17 (d, J = 7.8 Hz, 1H), 2.89-2.83 (m,
1H), 1.23-1.18 (m, 6H);

13

C NMR (acetone-d6, 126 MHz): δ 179.9, 171.2, 167.6, 154.7, 153.8,

153.4, 158.9, 148.9, 148.7, 137.5, 136.7, 135.3, 135.1, 129.1, 128.6, 128.5, 126.9, 121.1 84.6,
81.0, 76.1, 76.0, 70.3, 70.1, 53.9, 53.8, 51.7, 36.8, 35.7, 18.4; ESI MS (m/z) calculated for
C40H39N6O12, [M-H] 795.3; found 795.2.
N-Isobutyryl-5’-L-Ser(Ot-Bu)

methyl

ester-2’,3’-di-O-(carbobenzyloxy)

guanosine

(2.15).Yield: 67%; light brown powder; m.p.= 91 oC; TLC (DCM:MeOH 95:5): Rf = 0.55;
[ ]

-8.01 (c 0.1, acetone); IR (KBr) υmax (cm-1) = 3172, 2975, 1751, 1679, 1611, 1564, 1388,

1274, 1249, 1154, 1091, 1026, 901, 783, 757; 1H NMR (acetone-d6, 500 MHz): δ 12.06 (s, 1H),
10.43 (s, 1H), 8.34 (s, 1H), 7.84 (d, J = 8.3 Hz, 1H), 7.45-7.32 (m, 10H), 6.25 (d, J = 7.3 Hz,
1H), 5.93 (dd, J = 7.3, 4.9 Hz, 1H), 5.75 (dd, J = 4.6, 1.2 Hz, 1H), 5.32 (dd, J = 10.8, 22.9 Hz,
2H), 5.21 (dd, J = 11.8, 24.7 Hz, 2H), 4.95 (d, J = 1.5 Hz, 1H), 4.78-4.76 (m, 1H), 3.74 (d, J =
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3.4 Hz, 1H), 3.72 (s, 3H), 2.91-2.82 (m, 1H), 2.88-2.84 (m, 1H), 1.12 (s, 9H), 1.24 (d, J = 7 Hz,
6H); 13C NMR (acetone-d6, 126 MHz): δ 180.0, 170.1, 167.5, 154.7, 153.9, 153.4, 148.9, 148.8,
137.6, 135.3, 135.1, 128.6, 128.5, 121.2, 84.6, 81.2, 76.4, 75.9, 73.4, 70.2, 61.3, 53.1, 51.8, 35.7,
26.6, 19.9, 18.4; ESI MS (m/z) calculated for [M+H] C38H45N6O13, 793.3; found 794.2.
N-Isobutyryl-5’-L-Asp(Ot-Bu)-methyl

ester-2’,3’-di-O-(carbobenzyloxy)

guanosine

(2.16).Yield: 70%; light brown powder; m.p.= 64 oC; TLC (DCM:MeOH 95:5): Rf = 0.67;
[ ]
1

-8.46 (c 0.1, acetone); IR (KBr) υmax (cm-1) = 2977, 1759, 1717, 1684, 1275, 1155, 783;

H NMR (acetone-d6, 500 MHz): δ 11.91 (s, 1H), 10.55 (s, 1H), 8.23 (s, 1H), 7.99 (d, J = 3 Hz,

1H), 7.43-7.34 (m, 10H), 6.25 (d, J = 7.3 Hz, 1H), 6.00 (dd, J = 5.1, 7.1 Hz, 1H), 5.76 (dd, J =
2.4, 4.9 Hz, 1H), 5.21 (dd, J = 7, 19 Hz, 2H), 5.12 (dd, J = 13.8, 25.9 Hz, 2H), 4.94-4.89 (m,
1H),4.85 (d, J = 2 Hz, 1H), 4.06 (q, J = 6.8 Hz, 1H), 3.69 (s, 3H), 2.94-2.93 (m, 1H), 2.88-2.85
(m, 1H), 1.39 (s, 9H), 1.24 (d, J = 6.3 Hz, 6H); 13C NMR (acetone-d6, 500 MHz): δ 180, 170.5,
170.1, 170.0, 167.3, 154.7, 153.8, 153, 148.8, 148.7, 138.2, 138.0, 135.3, 135.1, 131.2, 128.6,
128.5, 121.5, 85.2, 81.4, 80.9, 80.8, 76.0, 75.1, 70.3, 70.1, 60.0, 59.6, 52.0, 48.9, 37.0, 35.7, 19.9,
18.5, 18.4; ESI MS (m/z) calculated for C39H44N6O14 [M+], 820.8; found 819.7.
N-Isobutyryl-5’-hexadecyl-2’,3’-di-O-(carbobenzyloxy) guanosine (2.17).Yield: 70%; light
brown viscous liquid; TLC (DCM:MeOH 95:5): Rf = 0.9; [ ]

-2.68 (c 0.2, acetone); IR (KBr)

υmax (cm-1) = 3321, 2924, 2853, 1722, 1710, 1692, 1679, 1513, 1462, 1451, 1384, 1257, 1176,
1101, 1034, 843, 805, 761, 742; 1H NMR (methanol-d4, 500 MHz): δ 8.70 (s, 1H), 7.36-7.21 (m,
10H), 6.27 (d, J = 6.7 Hz, 1H), 5.14 (m, 2H), 5.07 (m, 1H), 4.99 (m, 2H), 4.59 (s, 1H), 2.90 (m,
2H), 2.65 (m, 1H), 1.64 (m, 2H), 1.42-1.13 (m, 34H), 0.91-0.88 (m, 3H); 13C NMR (methanol-d4,
126 MHz): δ 231.3, 191.5, 189.1, 187.9, 155.7, 155.2, 144.3, 136.8, 136.4, 129.8, 129.76, 129.4,
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99.5, 94.3, 84.4, 71.6, 71.3, 42.7, 41.1, 37.2, 35.5, 33.2, 30.9, 30.8, 30.4, 29.1, 27.6, 23.8, 14.5;
ESI MS (m/z) calculated for [M+] C46H62N6O10, 859.0; found 858.6.
N-Isobutyryl-5’-N-Boc-L-Lys(OMe) guanosine (2.18). N-Isobutyryl-5’-N-Boc-L-Lys(OMe)2’,3’-di-O-(carbobenzyloxy) guanosine 2.13 (100 mg, 0.11 mmol) was dissolved in EtOH (2
mL) and 10% Pd/C (10 mg) was added. The mixture was stirred under an atmosphere of H 2 for
90 min at room temperature until TLC indicated complete reaction. The reaction mixture was
filtered through a pad of Celite and washed with MeOH. The filtrate was concentrated using a
rotary evaporator to afford the product 2.18 (68.8 mg, 0.11 mmol) as a solid. Yield: 99%; light
yellow powder; m.p.= 132 oC; TLC (DCM:MeOH 95:5): Rf = 0.36; [ ]

-13.5 (c 2.0, acetone);

IR (KBr) υmax (cm-1) = 3307, 2934, 1772, 1678, 1562, 1403, 1165, 948, 865, 757; 1H NMR
(acetone-d6, 500 MHz): δ 8.26 (s, 1H), 7.74 (d, J = 6.5, 1H) 6.00 (d, J = 6.5 Hz, 1H), 5.94 (s,
1H), 4.80 (s, 1H), 4.56 (s, 2H), 4.46 (d, J = 5.5 Hz, 1H), 3.69-3.66 (m, 2H), 3.04 (d, J = 6.5 Hz,
2H), 2.94-2.91 (m, 2H), 2.80 (s, 1H), 2.78 (s, 1H), 1.86-1.85 (m, 1H), 1.78-1.76 (m, 1H), 1.48 (d,
J = 4.5 Hz, 2H), 1.39 (s, 13H), 1.29-1.24 (m, 6H).

13

C NMR (acetone-d6, 126 MHz): δ 179.9,

172.3, 169.7, 155.9, 155.0, 149.1, 148.5, 137.8, 121.0, 110, 87.7, 83.9, 77.5, 74.1, 73.8, 56.9,
52.2, 51.6, 39.9, 35.7, 31.0, 22.8, 18.5, 18.4, 18.0; ESI MS (m/z) calculated for C26H40N7O10,
[M+H] 610.6; found 610.3.
N-Isobutyryl-5’-N-Boc-L-Lys(OMe)-2’,3’-di-O-(palmitoyl) guanosine (2.19) : Palmitoyl
chloride (108 mg, 0.39 mmol) and DMAP (5 mg, 0.04 mmol) were added to a solution of
guanosine 2.18 (0.8 g, 0.13 mmol) in dry pyridine (2.5 mL) at 0 °C. The reaction mixture was
stirred at room temperature for 2 h. The solution was then concentrated in vacuo, partitioned
between DCM (20 mL) and brine (10 mL) and dried over MgSO4. The crude product was
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concentrated and purified by silica gel column chromatography using DCM/MeOH (90/10)
yielding 2.19 (0.14 g, 0.13 mmol) as a white solid. Yield: 99 %; off white powder; m.p.= 51-53
C; TLC (DCM:MeOH 90:10): Rf = 0.6; [ ]

o

-16 (c 1.0, acetone); IR (KBr) υmax (cm-1)= 2916,

2850,1741, 1721, 1692, 1678, 1636, 1607, 1563, 1468, 1410, 1366, 1249, 1172, 945, 738, 721;
1

H NMR (DCM-d2, 500 MHz): δ 12.1 (s, 1H), 9.46 (s, 1H), 7.79 (s, 1H), 7.42 (d, J = 8 Hz, 1H),

6.01 (d, J = 5.5, 1H) 5.97 (dd, J = 4, 5 Hz, 1H) 5.77 (t, J = 5 Hz, 1H), 4.76 (t, J = 5.75 Hz, 1H),
4.66 (d, J = 4 Hz, 1H) 4.49 (dt, J = 6, 10.5 Hz, 1H) 3.74 (s, 3H), 3.00 (dd, J = 7, 13 Hz, 2H), 2.69
(t, J = 7 Hz, 1H), 2.41 (m, 2H), 2.30 (m, 4H), 1.52-1.70 (m, 6H), 1.37-1.41(m, 9H), 1.22-1.33
(m, 56H), 0.86-1.12 (m, 6H);

13

C NMR (DCM-d2, 126 MHz): δ 179.7, 172.9, 172.4, 172.1,

168.0, 155.0, 148.4, 147.9, 138.6, 122.0, 87.6, 81.3, 72.1, 72.0, 52.4, 52.3, 36.1, 33.8, 33.6, 31.9,
31.1, 29.7, 29.6, 29.6, 29.5, 29.4, 29.3, 29.3, 29.2, 29.1, 29.0, 28.1, 24.8, 24.7, 24.5, 22.7, 22.6,
18.8, 18.6, 13.8. ESI MS (m/z) calculated for C58H100N7O12, [M+H] 1086.7; found 1086.7
N-Isobutyryl-5’-L-Lys(OMe)-2’,3’-di-O-(palmitoyl) guanosine hydrochloride (2.6) : To a
stirred solution of guanosine 2.19 (0.14 mg, 0.13 mmol) in CH2Cl2 (3 mL) was added TFA (4
mL, 51 mmol). The reaction mixture was stirred at room temrature for 3 h until TLC indicated
complete reaction. The solvent was evaporated and the crude residue was dissolved in CH 2Cl2 (3
mL) and 1M HCl (3 mL). The resulting biphasic mixture was stirred for 2 min, separated and
washed again with 1M HCl (2 x 3 mL) before the organic phase was isolated, dried over MgSO4
and evaporated to dryness giving the crude product 2.6 (0.13 g, 0.13 mmol) as off white powder.
Yield: 99 %; off white powder; m.p.= 186-189 oC; TLC (DCM:MeOH 95:5): Rf = 0.2; [ ]

-3

(c 1.0, MeOH); IR (KBr) υmax (cm-1) = 3418, 2917, 2850, 1746, 1681,1614, 1567, 1468, 1404,
1204, 1157, 1108, 1022, 800, 722; 1H NMR (DCM-d2, 500 MHz): δ 8.48 (s, 1H), 6.15 (d, J =
5.5, 1H), 5.95 (t, J = 5, 1H), 5.80 (d, J = 2, 1H), 4.44 (dd, J = 5, 8.5 Hz, 1H), 3.78 (s, 3H), 2.92
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(t, J = 7.5, 2H), 2.73 (t, J = 3, 1H), 2.43 (m, 2H), 2.30 (t, J = 6 Hz, 2H), 1.88 (t, J = 7.5Hz, 1H),
1.68 (m, 4H), 1.53 (s, 2H), 1.40 (m, 2H), 1.28 (m, 56H), 0.88 (d, J = 6.5 Hz, 6H).

13

C NMR

(acetone-d6, 126 MHz): δ 180.3, 172.1, 171.9, 171.8, 169.4, 138.7, 119.7, 86.1, 86.0, 81.6, 81.5,
73.7, 72.8, 72.7, 52.3, 51.6, 51.4, 39.0, 35.6, 35.5, 35.4, 33.1, 31.7, 30.3, 29.4, 29.2, 29.1, 28.9,
28.7, 26.6, 24.5, 24.4, 22.5, 22.3, 18.1, 18.0, 17.9, 13.1, 13.0. ESI MS (m/z) calculated for
C53H92N7O10, [M+H] 986.3; found 986.7.

Solid-Phase

Oligonucleotide

Synthesis

and

Characterization

data.

Synthesis

of

oligonucleotides was performed on an ABI 3400 DNA synthesizer using a 1 µmol scale
automated synthesis cycle on a Unylinker controlled pore glass (CPG) support (Chemgenes Co.).
DNA phosphoramidites (Chemgenes Co.) were dissolved in anhydrous MeCN as 0.1 M
solutions. The coupling times were 20 sec using 0.25 M 5-ethylthiotetrazole (ETT) in MeCN as
activator. The detritylation times were set to 2 min using a solution of 3% dichloroacetic acid in
DCM. Capping and oxidation steps were performed using a mixture of acetic anhydride/Nmethyl imidazole in MeCN and a solution of 0.01 M iodine in pyr/THF/H2O, respectively.
Following synthesis, oligonucleotides were cleaved from the CPG and deprotected with
NH4OH:EtOH (3:1) for 16 h at 55 ºC. The crude oligonucleotides were evaporated to dryness,
extracted from the CPG with autoclaved H2O (1 mL) and quantitated by UV/VIS
spectrophotometry. Crude oligonucleotides were purified by reverse-phase ion-pairing HPLC on
a Waters 2695 Alliance system equipped with a Nova-pak C-18 reverse phase column (3.9 x 150
mm, 4 µm particle size) and gradient elution method of 5-95% B over 23 min (B:20% MeCN in
0.1 M TEAA).
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Characterization of oligonucleotides by ESI MS. All spectra were acquired on an oligo HTCS
LCMS system courtesy of Dr. Mark Hail at Novatia LLC (Newtown, PA). Oligonucleotide
samples (100 pmol) were dissolved in 1 mL H2O and directly injected into ESI-MS. The data
were processed by ProMass software.

Polyacrylamide Gel Electrophoresis (native gel shift mobility assays). PAGE was conducted
under native conditions (no urea or formamide) to allow complex formation. The running buffer
was 1 X TAE (89 mM TRIS/Acetate, 2.5 mM EDTA, pH = 4.2). The loading buffer for sample
preparation was 30% sucrose in 10 X TAE buffer, pH = 4.2. The dried oligonucleotide samples
were dissolved in 15 µL of loading buffer, denatured at 90 oC for 2 min, annealed at room
temperature for 2.5 h and overnight at 5 oC and then incubated with ligand 2.6 (0-3.9 mM) at 37
ºC for 36 h. The samples were then loaded on a gel that consisted of 24 % acrylamide. The gel
was run at 250 V, 32 mA, 12 W for 3-5 h. The gel was visualized under UV shadowing at 260
nm.

Thermal denaturation experiments, Tm. Thermal denaturation studies were conducted on a
Varian UV-VIS Cary 300 dual beam spectrophotometer equipped with a termperature controller.
Complementary oligonucleotides were annealed in phosphate buffer that mimics physiological
ionic strength: 140 mM KCl, 5 mM NaH2PO4, 1 mM MgCl2, pH = 7.2. The solutions were
denatured at 90 ºC for 2 min then cooled to room temperature over 2.5 h and kept at 5 ºC
overnight prior to the addition of ligand 2.6. Ligand 2.6 was added in increasing concentrations
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to duplex GRP78 DNA (0-3.9 mM) and incubated at 37 oC for 36 h prior to thermal denaturation
experiments. The thermal melts were run from 5-90 ºC with temprature gradient increments of
0.5 ºC/min and data points collected every 0.5 ºC/min at 260 nm. The Tm measurements were
calculated according to the temperature at which 50% of the duplex denatured to single strands
from a plot comparing the changes in hyperchromicity vs temperature.

Circular Dichroism (CD) Spectroscopy. Samples were prepared as described in the thermal
denaturation

experiments

and

analyzed

using

an

Aviv

Circular

Dichorism

(CD)

Spectrophotometer (Model: 62A DS). CD spectra were collected on an average of three scans
using 1 nm bandwidth and 0.5 min step size at 25 oC from 310-210 nm. Samples were blank
corrected, smoothed and the data converted to molar ellipticity values from the equation [θ] = θ
/cl, where θ is the relative ellipticity (mdeg), c is the molar concentration of the DNA (µM) and l
is the path length of the cell (1 cm). The data was imported into Microsoft Excel and the CD
spectra were plotted in terms of molar ellipticity vs wavelength.

Dynamic Light Scattering (DLS). Dynamic light scattering (DLS) measurements were
performed on a 90plus particle size analyzer (Brookhaven Instruments Corporation) employing a
90° scattering angle and a 35 mW incident laser (658 nm). All samples were filtered through a
0.02 µm pore size membrane (Whatman ANOTOP, alumina based membrane). Samples were
measured at time = 0 and 36 hours, for 2.6 (3.9 mM) in the absence or presence of GRP78 DNA
(1.1 µM) in pH = 7.2 phosphate buffer (5 mM NaH2PO4, 140 mM KCl, 1 mM MgCl2). The
reported diameter was the average of 3 runs for each sample.
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Cell Viability. Cancer cell viability studies were performed by the Developmental Therapeutics
Program, Division of Cancer Treatment and Diagnosis, National Cancer Institute
(http://dtp.cancer.gov). Briefly, a panel of 60 human tumor cell lines for screening was grown in
RPMI 1640 medium containing 5% fetal bovine serum and 2 mM L-glutamine. For a typical
screening experiment, cells were inoculated into 96 well microtiter plates in 100 µL at plating
densities ranging from 5,000 to 40,000 cells/well depending on the doubling time of individual
cell lines. After cell inoculation, the microtiter plates were incubated at 37 °C, 5 % CO2, 95 % air
and 100 % relative humidity for 24 h prior to addition of 2.6. After 24 h, two plates of each cell
line are fixed in situ with TCA, to represent a measurement of the cell population for each cell
line at the time of addition of 2.6 (Tz). Aminoacyl nucleolipid 2.6, was solubilized in dimethyl
sulfoxide (10 µM) and added to the appropriate microtiter wells. Following addition of 2.6, the
plates were incubated for an additional 48 h at 37 °C, 5 % CO2, 95 % air, and 100 % relative
humidity. Cells were fixed in situ by the gentle addition of 50 µl of cold 50 % (w/v) TCA (final
concentration, 10 % TCA) and incubated for 60 minutes at 4°C. The supernatant was discarded,
and the plates were washed five times with tap water and air dried. Sulforhodamine B (SRB)
solution (100 µL) at 0.4 % (w/v) in 1 % acetic acid was added to each well, and plates are
incubated for 10 minutes at room temperature. After staining, unbound dye is removed by
washing five times with 1 % acetic acid and the plates are air dried. Bound stain is subsequently
solubilized with 10 mM trizma base, and the absorbance was read on an automated plate reader
at a wavelength of 515 nm. Using seven absorbance measurements [time zero, (Tz), control
growth, (C), and test growth in the presence of 2.6 (Ti)], the percentage growth inhibition was
calculated as:
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[(Ti-Tz)/(C-Tz)] x 100 for concentrations for which Ti>/=Tz

[(Ti-Tz)/Tz] x 100 for concentrations for which Ti<Tz.

Growth inhibition of 50 % (GI50) was calculated from [(Ti-Tz)/(C-Tz)] x 100 = 50. The drug
concentration resulting in total growth inhibition (TGI) is calculated from Ti = Tz. A net loss of
cells following treatment was calculated from [(Ti-Tz)/Tz] x 100 = -50.
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Figure 2.10. NCI 60 cancer cell line one-dose screen. Data is reported as a mean graph of the
percent growth of cells treated with 2.6 (10 µM) relative to no drug control and relative to time
zero number of cells. Growth inhibition is detected as values between 0 and 100 whereas cell
death is evaluated by values less than 0.
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CHAPTER 3: PHTHALOCYANINE-NUCLEIC ACID BIOCONJUGATES
AND THEIR APPLICATIONS IN CANCER
3.1 GENERAL INTRODUCTION
Metallo-phthalocyanines (MPcs) encompass an interesting class of photosensitizers
owning the ability to absorb light in the near-IR region (650-900 nm) of the electromagnetic
spectrum. Consequently, they exhibit fluorescence and/or the ability to convert ground state
triplet oxygen (3O2) to excited state singlet oxygen (1O2) for applications in photodynamic
therapy [1]. Their fruitful applications in photodynamic therapy have been linked to the
production of 1O2, a form of reactive oxygen species (ROS) that when produced in tumors leads
to desirable anti-cancer effects [2,3]. In spite of their potential in cancer therapy, MPcs have
exhibited poor water solubility due to their hydrophobic nature and tendency for aggregation
which limits their photo-oxidation properties. Moreover, the hydrocarbon-based MPcs own
limited chemical stability towards the ROS they produce and widespread dispersion in all tissue
types leading to cytoxicity which limits their therapeutic efficacy. In an effort to circumvent
these limitations, bioconjugation approaches have been developed to effectively functionalize
MPcs with bio-active moieties that may improve the ‘drug-like’ properties of the
photosensitizers.
Nucleic acid conjugation has been especially applied to MPcs to improve their biological
function (Figure 3.1). For example, uridine, 5-methyluridine, cytidine and 5-N-cytidine
derivatives have been conjugated axially to silicon(IV) phthalocyanines in an attempt to improve
their water solubility and minimize aggregation which limits ROS production [4]. This resulted
in a uridine-based silicon phthalocyanine (3.1) which exhibited potent photocytoxicity (IC50: 6
nM) in HepG2 hepatoblastoma cancer cells. In an attempt to improve the targeting abilities of
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MPcs, oligonucleotide conjugation techniques, featuring reductive amination, amidation and
Huisgen cylcoadditon were successfully employed to generate MPcs-oligonucleotide
bioconjugates, 3.2, [5]. Dimerization of water soluble MPcs with a palindromic
deoxyoligonucleotide sequence led to the hybridization of a ‘quenched’ hairpin. In the presence
of a complementary sequence, the hairpin, 3.3, unravels to form a duplex structure, 3.5, with
concomitant fluorescence release from the MPc [6]. These bioconjugates and related analogs,
3.6, have been effectively employed as near-infrared fluorescent biosensors for detection of PCR
gene amplification [7], DNA microarrays for gene mutation analyses [8] in addition to live cell
and in vivo imaging [9]. In a related case study, short antisense oligonucleotides conjugated with
MPcs, 3.7, showed the ability to target and bind to complimentary sequences for photo-oxidation
and DNA cleavage activity following a hot piperidine or 8-oxoguanine DNA glycosylase (Fpg)
treatment [10,11]. These conditions are known to cleave the phosphodiester bonds in
oligonucleotides at oxidized sites, with the 8-oxoguanine modification being the most prevalent
and susceptible for degradation [12]. Considering the relevance of oxidation in DNA damage and
repair, MPcs conjugated oligonucleotides may serve as useful probes for elucidating the
underlying mechanisms of gene expression at oxidized sites. Moreover, these finding may also
have important contributions towards the development of targeted forms of photodynamic
therapy. Combination approaches featuring Bcl-2 antisense oligonucleotides was shown to
sensitize radiation-induced fibrosarcoma tumor cells to a silicon phthalocyanine, which triggered
potent apoptosis [13]. Altogether, MPc-oligonculeotides form an interesting class of
bioconjugates with widespread applications in diagnostics and therapy.
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Figure 3.1. MPcs-nucleic acid conjugates for applications in detection and photodynamic
therapy [4-11,13].

3.2 CHAPTER OBJECTIVES
Inspired by their important implications in biology and medicine, this thesis chapter
delineates the discovery of a new perfluorophthalocyanine-cancer-targeting oligonucleotide (PcCTO) bioconjugate for potential anti-cancer therapy. In this study, the Pc-CTO was designed to
contain a chemically robust fluoroalkyl phthalocyanine, which replaced most of the C-H with CF bonds on the periphery of the macrocycle in order to withstand the production of ROS.
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Moreover, the zinc(II) perfluorophthalocyanines have been characterized as efficient generators
of reactive 1O2 for potent and long-lasting photodynamic effects [14]. In order to introduce an
element of specificity in our photodynamic therapy approach, a cancer-targeting oligonucleotide
(CTO), composed of an antisense sequence complementary to a portion of the Glucose
Regulated Protein of 78 kilodalton (GRP78) oncogene was used to generate the putative Pc-CTO
conjugate. In this manner, the CTO is proposed to target and bind to the GRP78 oncogene, while
inhibiting its protein translation. Moreover, in the presence of aerobic illumination, the Pc
activates reactive 1O2 for triggering potent apoptotic events in cancer (Figure 3.2). This
combination approach has proven to be effective in chemo-resistant tumors in an effort to
eradicate some of the more resilient forms of cancer [13]. Thus, the Pc-CTO forms the basis of
our cancer-targeting photodynamic therapy approach. The synthesis strategy was developed in
collaboration with Emily Borland (B.Sc. student) and Hemantbhai Patel (Ph.D. student) in the
laboratory of Dr. Sergiu M. Gorun (Department of Chemistry, Seton Hall University). Their
expertise in the material sciences encompass a broad range of pthalocyanine applications, such as
their use as artificial enzymes [15], anti-cancer drugs [14], photosensitizers for degradation of
azo dyes [16], and as redox catalysts [17]. In a collaborative effort with the Gorun group, this
thesis chapter describes the synthesis, characterization and GRP78 oncogene photocleavage
activity of a chemically robust Pc-CTO bioconjugate for potential cancer-targeted photodynamic
therapy.
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Figure 3.2. Mechanism of action of Pc-CTO bioconjugates.
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3.3.1 ABSTRACT
The

first

representative

of

a

functionalized

fluoroalkyl

phthalocyanine,

F48H7(COOH)PcZn, is reported. The complex generates 1O2 affording long-lasting photooxidation of an external substrate without self-decomposition. The carboxylic group couples with
an antisense oligonucleotide targeting GRP78 oncogenes, resulting in the F48H7PcZn-cancer
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targeting oligonucleotide (CTO). The bioconjugated fluorophthalocyanine effectively hybridizes
complementary GRP78 DNA and mRNA sequences. Piperidine cleavage assays reveal desired
photochemical oligonucleotide oxidative degradation for both F48H7PcZn-CTO:DNA and
F48H7PcZn-CTO:mRNA hybrids (Figure 3.3). This new materials strategy could be extended to
other functional fluorinated phthalocyanines - antisense oligonucleotide combinations for longlasting oncogene-targeting photodynamic therapy.

Figure 3.3. Graphical abstract representation of A. journal cover art image of
perfluorophthalocyanine-GRP78 DNA photo-oxidation and cleavage activity, in addition
to, B. perfluorophthalocyanine-GRP78 mRNA aerobic illumination and cleavage pattern
at oxidized sites [18].

3.3.2. INTRODUCTION
Photodynamic therapy (PDT) uses photosensitizers to produce reactive oxygen species,
ROS (e.g. singlet oxygen, 1O2), that kill tumor cells [2,3,19]. Advantageously, PDT does
not trigger immunosuppressive or myelosuppressive effects that accompany surgery,
chemotherapy or radiation treatments. Historically, the first successful clinical application
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of PDT in oncology was demonstrated over 100 years ago [20], with the first PDT drug
approved for bladder cancer in 1993 [21]. However, unfavorable photosensitizer
properties that lower therapeutic index, such as: poor water solubility, limited extinction
coefficients in the maximum tissue penetration NIR region (600-900 nm), poor clearance
from normal cells and photo-stability issues contributed to limited approval of PDT drugs
for clinical use. Moreover, poor tumor-targeting results in dispersion in all tissue types,
depressing efficiency and enhancing harmful side-effects. Most of the photosensitizers
used in oncology are based on the tetrapyrrole scaffold, such as, the porphyrins, chlorins,
corroles and phthalocyanines [19]. The phthalocyanines, in particular, are easily modified
while exhibiting high thermal and chemical stability, in addition to intense light
absorption toward the advantageous red spectral region [1].
In order to help mitigate current photosensitizers’ limitations, this chapter describes the
first example of a new class of functionalized fluoroalkyl phthalocyanine photosensitizers,
F48H7(COOH)PcZn, 3.10, in which most of the C-H bonds of the Pc macrocycle are
replaced by aromatic and aliphatic C-F bonds. The fluorinated phthalocyanines,
Fx(RF)yPcM , (Fx = fluorine, RF = perfluoro alkyl group, x + y  16, Pc = phthalocyanine
and M = metal) constitute an important class of chemically robust photosensitizers [22].
The fluorinated alkyl substituents, RF, in contrast to aromatic F groups are expected to
enhance the stability of the Pc macrocycle towards nucleophilic attack by the ROS that
the Pcs produce during the photodynamic events [23]. Thus, partial replacement of
aromatic F in perfluorophthalocyanine, F16PcM (M = Zn; x = 16, y = 0), with isoperfluoroalkyl groups (RF) to give octakis-(perfluoro-i-C3F7)-(perfluoro)PcM, F64PcM (x
= y = 8) was shown to improve the Pc’s solubility in organic solvents, depress the
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HOMO-LUMO gaps, thereby extending the Q-bands absorption in the 600-900 nm NIR
region, while retaining high ~105 molar extinction coefficients favouring efficient 1O2
production [24]. The RFPc macrocycle scaffold’s resistance to degradation prompted their
use as artificial enzymes [15], anti-cancer drugs [14], photosensitizers for degradation of
azo dyes [16], and as redox catalysts [17]. However, the lack of the R FPc’s specific tissue
distribution suggested the need for a targeting approach in our PDT applications. The
enhanced tissue localization of photosensitizers is particularly useful for potentially
increasing their therapeutic index. Strategies for specific tissue targeting include
anchoring protio Pcs onto bio-probes, following their functionalization with –COOH, NH2, -SO3H, -X (X = Cl, Br, I) groups [25,26] that thus facilitate Pc conjugation with
carbohydrates [27], nucleosides [4], oligonucleotides [5,28], peptides [29] and proteins
[30]. However, these approaches offer a limited therapeutic index for effective and longlasting PDT due to the decomposition of the protio Pcs by the ROS they produce [10,11].
Moreover, chemically less stable hydrocarbon-based Pcs coupled to short, arbitrary
oligonucleotide sequences have been reported in the literature [10,11]. However, to the
best of our knowledge, coupling a chemically robust fluoro Pc with an oligonucleotide
vector, Figure 3.4, targeting a DNA or mRNA oncogene, has not been reported.
The cancer-targeting oligonucleotide, CTO, was selected from the antisense DNA
sequence exhibiting potent Glucose Regulating Protein 78, GRP78 knockdown in
neonatal rat cardiomyocytes [31]. GRP78 functions as a chaperone that regulates protein
folding events in the lumen of the endoplasmic reticulum (ER) of all cell types [32]. In
cancer, GRP78 is overexpressed and localized on the cell surface where it exhibits a
myriad of signaling activities related to cancer initiation, production and metastatic spread
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[33]. The GRP78 oncogene is thus an excellent target for the development of potent and
selective anti-cancer strategies [34].

Figure 3.4. F48H7PcZn-GRP78 cancer-targeting oligonucleotide (CTO) bioconjugate, 3.14.

3.3.3. RESULTS AND DISCUSSION
The F48H7(COOH)PcZn, 3.10, was prepared in 21% isolated yield by reacting
perfluoro phthalonitrile 3.8, [35] with a carboxy phthalonitrile 3.9, [5] in a microwave
reactor, Scheme 3.1. Its composition and purity were confirmed by 1H,

19

F NMR and

HRMS (see Experimental Section).
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Scheme 3.1. Microwave-assisted solution-phase synthesis of F48H7(COOH)PcZn, 3.10.

The catalyst nuclearity and stability under the reaction conditions were established via
time-dependent UV-Vis spectroscopy. The solvent-independent Q-bands intensities and
linearity of the Lambert-Beer plot for 3.10 (Figure 3.5) reveal its lack of aggregation, a
key factor for avoiding the shortening of the Pc excited states lifetimes via intermolecular
interactions which lowers 1O2 production efficiency.
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b)

a)

Importantly, 3 remains unchanged (>99%) at the end of the photooxidation reaction thus
establishing its reactivity without self-decomposition. Taken together, this data
demonstrates the ability of the functionalized fluorophthalocyanine to exhibit single-site
structural characteristics in solution and to photooxidize an external substrate without
being decomposed by the 1O2 it produces.

c)

d)

Figure 3.5. UV-Vis electronic absorption spectra of F48H7(COOH)PcZn, 3.10 a) 3.10 (1-10 µM)
in chloroform; b) Lambert-Beer plot of the Q-band absorption maxima; c) normalized absorption
spectra of 3.10 in chloroform and ethanol; d) Time-dependent UV-Vis of 3.10 during the
photooxidation of β-citronellol in ethanol up to the time of complete consumption of O2, ~14,400
sec. (4 hrs.). No catalyst decomposition is observed. The Q-band absorptions, shifted toward the
red region of the spectrum are consistent with the expected effect of peripheral substitution by
electron-widthdrawing groups. The Q-bands split is due to the loss of the typical phthalocyanine
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4-fold symmetry, as noticed previously, for example, for a related zinc-phthalocyanine,
conjugated with deoxyribonucleosides. See B. Das, E. Tokunaga, M. Tanaka, T. Sasaki, and N.
Shibata, Eur. J. Org. Chem. 2010, 2010, 2878-2884.
Importantly, 3.10 generates 1O2 as demonstrated by the aerobic photo-hydroperoxidation
of β-citronellol (Figures 3.6a,b). The reaction obeys pseudo-first order kinetics with an
initial reaction rate of 27.8 μmol O2 min−1 that corresponds to a turnover frequency 460
mmol citronellol s−1 mol Pc−1. This rate is consistent with the 33.6 µmol O2 min-1 value
reported for the homoleptic F64PcZn, 3.11 [23,36]. In contrast, the hydrocarbon-based Pcconjugates are not stable, as exemplified by the loss of Q-bands intensities in the case of a
protio PcCo-oligonucleotide conjugate that is exposed to ROS [10]. The Pc complexes
with Zn and Al are presumably active in generating singlet oxygen, but the stability of the
Pc is not reported [11].

Figure 3.6. a) Photooxidation of β-citronellol in EtOH by 3.10, ("ZnPc"). ISC =
intersystem crossing; b) Time-dependent O2 titration at 25 oC. No reaction occurs in the
absence of either light or O2. See also Figure 3.10. The O2 was consumed in the
calculated stoichiometric amount.
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The carboxy group of the Pc catalyst, 3.10, was next coupled with the amino group of
the

solid-supported

CTO,

3’-TCGCGGCCGTTCTACTC-5’-C6-NH2,

3.13,

using

conventional amide coupling conditions [37] to yield after cleavage, deprotection and
HPLC purification the bioconjugate F48H7PcZn-CTO, 3.14, in isolated purity >95%
(Scheme 3.2).

Scheme 3.2. Conjugation of 3.10 to an antisense GRP78 deoxyoligonucleotide bound to a solid
support, 3.13.
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The hybridization of bioconjugate 3.14 with complementary GRP78 DNA, 3.15 and
mRNA, 3.16 sense strands, afforded the duplexes F48H7PcZn-CTO:DNA, 3.14:3.15, and
F48H7PcZn-CTO:mRNA, 3.14:3.16. These hybrids, soluble in phosphate buffers,
exhibited stable (Tm = 75 and 72 °C, respectively) temperature-dependent duplex to
single-strand transitions (Figure 3.7). Taken together, these results unambiguously
establish the ability of F48H7PcZn-CTO to target and bind to complementary GRP78
DNA and mRNA, affording thermally stable duplex structures, similar to the ones formed
by the native controls (Figure 3.7).

Figure 3.7. Thermal denaturation curves of PcDNA-DNA (3.14:3.15), PcDNA-RNA
(3.14:3.16), DNA-DNA (3.17:3.15), RNA-DNA (3.17:3.16) hybrids
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In order to examine the influence of Pc 3.10 on oligonucleotide hybrid structure, the
circular dichorism (CD) spectrum was collected (Figure 3.8). The CD spectrum of the duplex
formed with the native DNA hybrid showed a CD signature consistent with the cannonical Btype helix structure, with a characteristic broad maximum band in between 260 - 280 nm and a
minimum one at 248 nm [38]. Similarly, the control construct, formed with the DNA:RNA
hybrid shows an AB-type helical structure, with characteristic maximum band at 265 nm and a
broad minimum in between 250 – 230 nm [38]. In comparison, the CD spectra of the
PcDNA:DNA and PcDNA:RNA hybrids exhibit structures similar to the ones formed from the
native controls. Taken together, this data validates the capabilities of the PcDNA bioconjugate,
3.14, to form stable duplex structures with complementary oligonuceotides for biological
evaluation.

Figure 3.8. CD spectra of PcDNA-DNA (3.14:3.15), PcDNA-RNA (3.14:3.16), DNA-DNA
(3.17:3.15), RNA-DNA (3.17:3.16) hybrid
78

Given the ability of F48H7(COOH)PcZn, 3.10, to generate and survive 1O2 production,
the photoreactivity of F48H7PcZn-CTO, 3.14, hybridized with complementary GRP78
DNA and mRNA, i.e. 3.14:3.15 and 3.14:3.16, respectively, was explored. This reactivity
is critically important for establishing the ability of bioconjugates to generate singlet
oxygen and the capacity of the latter to oxidatively cleave the thermally stable
oligonucleotides. Thus, illumination with a 300 W halogen light for 12 hrs in the presence
of O2 followed by hot piperidine treatment induced site-specific cleavage along the
oligonucleotide backbone at oxidized sites [12], Figure 3.9. In contrast, no degradation
occurred in the absence of light and/or O2, or using unlabeled controls (see also Figure
3.16).

Figure 3.9. 24% PAGE for the photo-oxidation and piperidine cleavage pattern of a)
3.14:3.15 and b) 3.14:3.16. Lane 1: light, but no O2. Lane 2: no light, but with O2. Lanes
3-13, time points from 0-12 hrs.
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3.3.4. CONCLUSIONS
In conclusion, an entry point into a new family of highly fluorinated phthalocyanines
was established. A highly fluorinated, functionalized molecule was synthesized and
shown to generate 1O2 without self-decomposition, underscoring its potential in PDT [1-3]
and other applications [39]. Its coupling with a cancer-targeting oligonucleotide vector
proved useful in directing GRP78 DNA and mRNA oncogene stable binding, but also
cleavage

upon

aerobic

illumination.

The

photoactive

and

chemically

robust

fluorophthalocyanine-CTO bioconjugates encompass a new class of potential anticancer
agents. Variations in the fluorinated phthalocyanine structure, coupled with variations in
the types of vectors may facilitate the targeting of a broad range of oncogenes and cancer
types.

3.3.5. EXPERIMENTAL SECTION
Materials and Methods. All commercial reagents and solvents (ACS grade) were used without
further purification, unless stated otherwise. Cesium fluoride was dried in vacuo for 2 days over
P4O10 at 100 °C prior to use. Acetonitrile (MeCN) used for the synthesis of the perfluoro-(4,5diisopropyl)phthalonitrile precursor was freshly distilled from calcium hydride before use.
Perfluoro-(4,5-diisopropyl)phthalonitrile [35], 3.8 and 4-(3,4-dicyanophenoxy)benzoic acid [5],
3.9 were prepared according to a published literature procedure. Deuterated solvents were
purchased from Cambridge Isotope Laboratories. Chromatographic separations were carried out
on silica gel 60 (63–200 μm). Thin-layer chromatography was performed on pre-coated silica gel
60 F254 plates.
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1

H, 13C and 19F NMR spectra were obtained at ambient temperature on a Varian 500 MHz NMR

spectrophotometer. 1H and 13C NMR spectra were referenced internally to residual solvent peaks
and 19F chemical shifts were referenced to an internal CFCl3 (δ = 0.00) standard. NMR spectral
data were processed using the ACD (version 12.01) software. Infrared spectra were obtained on a
Nicolet FT-IR spectrophotometer. Electronic absorption spectra were collected using a Perkin
Elmer UV-Vis spectrophotometer. High-resolution mass spectra (HRMS) were acquired at the
University of Michigan (Ann Arbor, MI) by electron spray ionization in negative mode. A
microwave CEM Discovery microwave reactor was used for Pc synthesis. Reactions were
performed using a septum-sealed reaction vessel (10 mL) which included a thick-walled Pyrex
glass reaction vessel sealed with Teflon septa caps. Melting points were taken using capillary
tubes under air in a Mel-Temp apparatus and are uncorrected.

Synthesis of F48H7(COOH)PcZn, 3.10. 3,6-difluoro-4,5-bis(perfluoropropan-2-yl) benzene-1,2dinitrile 3.8, (100 mg, 0.199 mmol), 4-(3,4-dicyanophenoxy)benzoic acid, 3.9, (53 mg, 0.199
mmol), zinc(II) acetate (18.3 mg, 0.999 mmol) and catalytic amounts of ammonium molibdate
were mixed with few drops of nitrobenzene in a glass vial, sealed with a Teflon cap and heated in
the microwave reactor at 190 oC for 20 minutes. The crude product was purified by column
chromatography on silica gel using 4:6 v/v hexane/acetone. F64PcZn was isolated as a green-blue
solid (31% yield) while the desired product, F48H7(COOH)PcZn, 3.10, was isolated as a green
solid. The latter was further purified by chromatography using 1:9 v/v of MeCN (contain 0.1 %
TFA)/Hexane. Yield: 25.3 mg, 20.8%. 1H NMR (500 MHz, Acetone-d6): δ 7.13 - 7.31 (m, 2 H),
7.46 - 7.59 (m, 1 H), 7.62 - 7.78 (m, 1 H), 7.80 - 8.20 (m, 3 H). 19F NMR (470 MHz, Acetoned6): δ -164.57 (br. s., 6 F), -104.23 (br. s., 6 F), -72.87- -70.37 (m, 36F). IR (NaCl, cm-1): 2957,
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2924, 2853, 1726, 1591, 1462, 1379, 1274, 1122, 1074, 951, 801. HRMS (-ve ESI) m/z [M+Cl] calcd: 1862.8938; obsd: 1862.8964. UV-Vis (CHCl3) λmax (log ε) 710 (5.02), 672 (4.96), 608
(4.32), 378 (4.68) nm (L mol-1 cm-1).

Photo-oxidation of -citronellol. The catalyst F48H7(COOH)PcZn, 3.10, was dried to constant
weight at 150 °C prior to use. Photo-oxidation were performed at 25±0.2 °C under oxygen
atmosphere (99.998% purity) in a closed, 100 mL double-walled jacketed glass vessel, while
stirring at 180 rpm for 4 hrs. The temperature was kept constant with the use of a Lauda
Brinkmann Ecoline RS-106 refrigerating water bath circulator. Oxygen was dosed with a
Dosimat 665 dispenser (Metrohm, Switzerland) and its consumption was measured with a
manometer in a closed system (see Figure 3.10). Catalyst stability measurements were performed
by UV-Vis absorption measurements (300-800 nm) of aliquots (1 mL, 0-4 h) extracted
periodically from the reaction mixture. The photooxidation reaction mixture consisted of Pc,
3.10 (20±2 μM) catalyst dissolved in ethanol (50 mL) with (S)-(–)-citronellol (180 μL, 1.0
mmol). Illumination was performed using the 300 W halogen lamp of a Kodak Ektagraphic III
slide projector, creating a light intensity of 2.5±0.1 × 105 lux, measured at the outer wall of the
reaction vessel with an EA33 model light meter (Extech Instruments, Waltham, MA).
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Figure 3.10. Schematic representation of the catalytic oxidation equipment. (1) Gas inlet; (2)
thermostated water inlet; (3) computer-monitored oxygen consumption; (4) Dosimat; (5) oxygen
reservoir; (6) three-way tap; (7) electrical couple for Dosimat dispenser control; (8) mercury
switch; (9) magnetic stirrer; (10) 100 mL double-walled glass reaction vessel; (11) solution inlet;
(12) light source.

Solid-Phase Oligonucleotide Synthesis. Synthesis of alkyl (C6) amino linker GRP78 antisense
oligonucleotide, 3.17, (5’-CTTCATCTTGCCGGCGCT-3’), sense oligonucleotide, 3.15, (5’AGCGCCGGCAAGATGAAG-3’)

and

sense

RNA

oligonucleotide,

3.16,

(5’-

AGCGCCGGCAAGAUGAAG-3’) sequences were performed on an Unylinker controlled pore
glass (CPG) support (Chemgenes Co.) using a 1 µmol scale automated synthesis cycle on a ABI
3400 DNA synthesizer. All phosphoramidites were dissolved in anhydrous MeCN yielding 0.1
M solutions. The coupling times were 20 sec using 0.25 M 5-ethylthiotetrazole (ETT) in MeCN
as activator. The detritylation times were set to 2 min using a solution of 3% dichloroacetic acid
in CH2Cl2 (DCM). Capping and oxidation steps were performed using a mixture of acetic
anhydride/N-methyl imidazole in MeCN and a solution of 0.01 M iodine in pyr/THF/H2O,
respectively. Following synthesis, oligonucleotides were cleaved from the CPG and deprotected
with NH4OH:EtOH (3:1 v/v) for 16 hrs at 55 ºC. The crude oligonucleotides were evaporated to
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dryness, extracted from the CPG with autoclaved H2O (1 mL) and quantitated by UV/Vis
spectrophotometry. Crude oligonucleotides were purified by reverse-phase ion-pairing HPLC on
a Waters 2695 Alliance system equipped with a Nova-pak C-18 reverse phase column (3.9 x 150
mm, 4 µm particle size) and gradient elution method of 5-95% A over 23 min (A: 20% MeCN in
0.1 M TEAA). The molecular masses of pure oligonucleotides were confirmed by ESI-MS. In
the case of RNA, 3.16, CPG-bound RNA was transferred into autoclaved eppendorf tubes and
treated with a 1 mL solution of 1:1 v/v ammonium hydroxide/methylamine (AMA) and heated at
65 °C for 10 min. AMA was evaporated in-vacuo and the CPG was washed twice with
autoclaved water (500 µL). Crude RNA oligonucleotides were re-suspended in a mixture of 1:1
v/v DMSO:triethylamine trihydrofluoride (125 µL) to complete the 2’-desilylation reaction at 65
°C for 90 min. The crude RNA was precipitated from the reaction mixture with 3 M NaOAc (25
µL) in n-BuOH (1 mL). Precipitation was completed on dry ice for 2 hrs prior to centrifugation
(12,000 rpm) leaving the crude oligonucleotides as a solid white pellet. Crude oligonucleotides
were re-suspended in autoclaved water (1 mL) and the yields were determined by UV
absorbance measurements at 260 nm. Crude RNA was purified by reverse-phase ion-pairing
HPLC and characterized by ESI-mass spectrometry as previously described.
Preparation of the flouro-Pc antisense oligonucleotide bioconjugate, 3.14. The bioconjugate
was produced on solid-phase, by combining the carboxy-derived perflouro phthalocyanine, 3.10,
(3 eq, 5 mg) with the GRP78 antisense 3.13, oligonucleotide-bound resin (1 µmol). A coupling
reagent (HCTU, 1.2 mg, 3 eq) was added, the mixture was suspended in DMF (1 mL) and a base
(NMM, 0.66 µL, 6 eq) was added to initiate the reaction. The reaction was performed overnight
(16 hrs) at room temperature, in an overhead shaker. The mixture was filtered, and the resin was
washed successively with DMF (3 x 10 mL), MeCN (3 x 10 mL), THF (3 x 10 mL) and DCM (3
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x 10 mL) and dried in vacuo. The fluoro-Pc oligoncucleotide-bound resin was cleaved and
deprotected using NH4OH:EtOH (1 mL, 3:1 v/v) for 24 hrs at 55 °C. The solution was
centrifuged and concentrated to a solid pellet. The crude oligonucleotide was extracted in
autoclaved water (1 mL), quanitated by UV-Vis spectrophotometry (Crude OD: 29, Absorption
coefficient (ε): 159,100, Path-length: 1 cm, Concentration: 182 M)* analyzed and purified by
ion pairing reverse-phase HPLC as described above. The desired fluoro-Pc oligonucleotide
bioconjugate, 3.14, was isolated in purity >95% and 18% yield (1.35 mg) characterized by ESI
mass spectrometry (See Table 3.1) and quanitated by UV-Vis spectrophotometry (Pure OD: 3,
Absorption coefficient (ε): 159,100, Path-length: 1 cm, Concentration: 19 M)*
* Absorption coefficient (ε) was calculated using Intergrated DNA Technologies’ OligoAnalyzer
3.1. Optical Density (OD) was converted to Concentration using converter.

Figure 3.11. UV-Vis electronic absorption spectra of F48H7PcZn-CTO bioconjugate, 3.14.
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Figure 3.12. HPLC trace of GRP78 CTO, 3.13.
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Figure 3.13. HPLC trace of GRP78 DNA, 3.15.
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Figure 3.14. HPLC trace of GRP78 mRNA, 3.16.
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Figure 3.15. HPLC trace of F48H7PcZn-CTO bioconjugate, 3.14.
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UV-Vis Spectroscopy. Optical absorption spectra were acquired with a Perkin Elmer or a Varian
Cary 300 dual beam UV-Vis spectrophotometer. Absorption values were obtained for 3.10 (10
µM) in chloroform/ethanol or for oligonucleotides 3.13-3.17 (0.67 µM) in a physiologically
relevant phosphate buffer (140 mM KCl, 5 mM NaH2PO4, 1 mM MgCl2, pH = 7.2). Absorption
measurements were recorded at 300-800 nm for 3.10, 3.14 and 260 nm for oligonucleotides 3.133.17, which were quantified according to the Beer-Lambert law. The data was averaged over a
range of five different absorbance scans and reported as a mean value with a standard deviation
no greater than 0.1 a.u.

Electron spray ionozation mass spectrometry. All oligonucleotide mass spectra were acquired
on an HTCS LCMS system at Novatia, LLC for 100 pmol of oligonucleotide sample dissolved in
1 mL H2O and directly injected for ESI-MS. The data was processed by a ProMass software
(Table 3.1). For high-resolution mass spectrometry of Pc, 3.10, the sample was analyzed by
direct injection on TOF/Q-TOF Mass Spectrometer at University of Michigan, Mass
Spectrometry service laboratory.
Table 3.1. Electron spray mass spectrometry data for oligonucleotides 3.13-3.17.
Sequence

Calculated
Mass

Observed Mass

3.14 F48H7PcZn –CONH-C6- 5’-CTTCATCTTGCCGGCGCT-3’

7410.6

7411.4

3.15 5’-AGCGCCGGCAAGATGAAG-3’

5582.7

5583.1

3.16 5’-AGCGCCGGCAAGAUGAAG-3’

5856.1

5856.1

3.17 5’-CTTCATCTTGCCGGCGCT-3’

5417.5

5417.1

3.13 NH2-C6-5’-CTTCATCTTGCCGGCGCT-3’

5596.7

5596.8
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Thermal denaturation experiments, Tm. Thermal denaturation studies were conducted on a
Varian UV-Vis Cary 300 dual beam spectrophotometer equipped with a termperature controller.
Complementary DNA and RNA oligonucleotides were annealed in a physiologically relevant
phosphate buffer (140 mM KCl, 5 mM NaH2PO4, 1 mM MgCl2, pH = 7.2). The solutions were
denatured at 95 ºC for 1 min then cooled to room temperature over 2.5 h and kept at 4 ºC
overnight prior to conducting experiementation. The thermal melts were run from 5-90 ºC with
temperature gradient increments of 0.5 ºC/min and data points collected every 0.5 ºC/min at 260
nm. The Tm measurements were calculated according to the temperature at which 50% of the
duplex denatured to single strands from a plot comparing the changes in hyperchromicity vs
temperature.
Circular Dichroism (CD) Spectroscopy. Samples were prepared as described in the thermal
denaturation

experiments

and

analyzed

using

an

Aviv

Circular

Dichorism

(CD)

Spectrophotometer (Model: 62A DS). CD spectra were collected on an average of three scans
using 1 nm bandwidth and 0.5 min step size at 25 oC from 310-210 nm. Samples were blank
corrected, smoothed and the data converted to molar ellipticity values from the equation [θ] = θ
/cl, where θ is the relative ellipticity (mdeg), c is the molar concentration of the DNA (µM) and l
is the path length of the cell (1 cm). The data was imported into Microsoft Excel and the CD
spectra were plotted in terms of molar ellipticity vs wavelength.
Photo-oxidation and chemical cleavage assay. The Pc labeled GRP78 antisense
oligonucleotide, 3.14, (6.7 µM) was annealed with a complementary DNA or RNA sequences
(3.15-3.16, 6.7 µM) in a physiological phosphate binding buffer (140 mM KCl, 1 mM MgCl 2, 5
mM Na2PHO4 adjusted to pH 7.2). The unlabeled native GRP78 oligonucleotide sequences,
3.15-3.17, were also hybridized and used as controls. Air was passed inside the microtube reactor
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(1 mL) to saturate the solution with oxygen. The reaction was initiated by shining light (>250000
Lux) onto the samples at room temperature (22 oC). Aliquots (7 µL), collected at different time
points (0-12 h), were transferred to separately sealed microtubes and stored in the absence of
light at 4 °C until further use. Control experiments were also conducted as previously described
in the absence of oxygen and/or light. Following the completion of the photooxidation reaction,
the aliquots were dissolved in 1 M piperidine in water (150 µL, pH 12) and incubated for 45 min
at 95 °C. The samples were centrifuged and concentrated to dryness on a Savant speedvac
concentrator. Samples were then re-suspended in 80% formamide in autoclaved water (10 µL)
and loaded on a 24% denaturing (7 M urea) PAGE. Following electrophoresis gels were
visualized under short-UV shadowing (265 nm) and subsequently placed in a Stains-All®
(Sigma) dye solution (25 mg Stains-All®, 50 mL isopropyl alcohol, 25 mL formamide, 125 mL
water) for visualizing the resolved bands.

Figure 3.16. 24% PAGE for the photo-oxidation and piperidine cleavage reactions. a) 3.17:3.15
and b) 3.17:3.16. Lane 1: light, but no O2. Lane 2: no light, but with O2. Lanes 3-12 or 13, time
points from 0-12 hrs.
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CHAPTER 4: PROGRESS TOWARDS THE SYNTHESIS, STRUCTURAL
ANALYSIS AND GRP78 BINDING OF A DIACYLHYDRAZINE LINKED
DINUCLEOSIDE
4.1 GENERAL INTRODUCTION
A DNA hairpin is formed from a palindromic single stranded DNA (ssDNA) sequence
which folds into a structure containing a base-pairing stem and a non-pairing loop (Figure 4.1).
The DNA hairpin secondary structure is prevalent in naturally occurring DNA, such as those
associated with the regulation of gene expression, modulating protein function and dictating the
activity of mobile genetic elements [1]. These are likely to be ssDNA found within viruses,
bacterial plasmids, transposons, and integrons.

Figure 4.1. General structure of a DNA hairpin. Figure adapted from: http://www.nfstc.org/

The favorable formation of a stem-loop structure is dependent on the stability of the
resulting base-pairing stem and non-pairing loop regions which is typically dictated by salts [2].
For example, hairpins with small loop sizes have been found to be stabilized by Na+ ions (100
mM NaCl), more so than the addition of Mg2+ ions (2.5 mM MgCl2) which were found to
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destabilize intraloop interactions in short hairpin DNA (shDNA) motifs. Moreover, the sequence
dependence on the thermal stability of shDNA has also been studied in depth by Bevilacqua and
co-workers [3-7]. By temperature-gradient gel electrophoresis (TGGE) and in-vitro selection,
DNA triloops, d(cGNAg) and tetraloops d(cGNNAg) (d = DNA; closing base pair in lower case;
loop in upper case; N = A, C, G, or T) containing a closing C:G base-pair have shown
exceptional thermal stabilities which paralleled those found within similar short hairpin RNA
(shRNA) sequences [3,7]. This is partially due to the enhanced G:C base-pairing affinity, which
shares three H-bonds compared to the two canonical A:T H-bonds or the non-pairing acyclic
alkyl (C3) linkers that have destabilized shDNA structures [4,5]. These studies underscore the
cooperative network of intraloop and loop-closing interactions which maintain the structural
integrity and stability of shDNA sequences [6]. Interestingly, loops that are less than three bases
are energetically unfavorable and have not been found in shDNA and related structures. Thus,
modifications that can mimic and/or stabilize turn conformations may lead to the generation of
stable shDNA analogs for structure-activity relationship studies in medicinal chemistry
applications.
The development of modified nucleic acids through chemical synthesis has enabled the
incorporation of synthetic modifications within naturally occurring sequences to improve their
structure-function properties. For example, nonionic analogues of nucleic acids have been
prepared to increase cellular permeability and nuclease resistance in biological media [8]. More
specifically, a variety of phosphodiester backbone modifications have been explored in order to
improve DNA structural stability without compromising biological activity (Figure 4.2).
Historically, backbone modified oligonucleotides have been prepared for improving the
therapeutic efficacy of DNA in antisense, antigene or aptamer methods of silencing malignant
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gene expression [9]. Only a few examples have been reported of backbone modifications in
DNA that may pre-organize biologically relevant secondary structures for enhanced therapeutic
applications (Figure 4.3) [10-13].

Figure 4.2. Structures of nonionic backbone modified oligonucleotides. Modifications include
replacement of the native phosphodiester bond with: amide, 4.1, thioacetamide, 4.2, triazole, 4.3,
alkylamine, 4.4, formacetal, 4.5, thioformacetal, 4.6, dimethylenesulfone, 4.7, N-acylsulfamide,
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4.8, oxyamine, 4.9, or methylene(diamide), 4.10, trans-butene, 4.11, diisopropylsilyl, 4.12, and
N-oxyamide, 4.13 [8,9].
For example, the synthesis and structural properties of alkane-linked shDNA
demonstrated hairpins possessing a stilbenediether linker, 4.14, with greater structural stability
when related to those that contained a C12 alkyl linker, 4.15, and a hexa(ethylene glycol) linker,
4.16, (i.e. stilbenediether > alkyl > glycol) [10]. These results indicated that hydrophobic
interactions in between the linkers and the closing A:T base-pair were partially responsible for
shDNA stability. Moreover, the stabilizing influence of the stilbenediether linker also suggested
the importance of structural rigidity within the shDNA loop domain [10,12]. This privileged
structure was found to pre-organize the putative turn conformation within shDNA via a cis-totrans photoisomerization process that was detected by UV-Vis, CD and NMR spectroscopy.
Similarly, a perylenediimide-linked DNA hairpin, 4.17, was shown to stabilize monomeric
shDNA structures in the absence of salt and dimerized sequences in >50 mM NaCl [11]. In
comparison, increasing alkyl chains (C8-C14) led to an increase in shDNA thermal stability,
however, with lengthier alkyl chains (>C14) a drop in melting temperature was observed [10].
Replacement of natural T4 and T5 loops with heptakis(ethylene glycol) and octakis(ethylene
glycol), respectively, resulted in an enhancement in shDNA thermal stability [10,13]. Thus,
replacement of the non-pairing nucleotides within the loop domain of shDNA with flexible and
rigid alkyl linkers highlights the importance of hydrophobicity and conformation in dictating
shDNA structural stability. The implications of stabilizing loop structures in shDNA not only
provides greater insight into their structure and thermodynamic stabilities but also introduces
modification that may improve their biological properties for applications in medicinal
chemistry.
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Figure 4.3. Structures of loop-modified shDNA [10-13].

4.2 CHAPTER OBJECTIVES
The aim of this thesis chapter is related to the synthesis and structural characterization of
a novel backbone modified dinucleoside. The putative diacylhydrizine-linked T:A dimer is
proposed to mimic shDNA by conferring a stable turn structure which orients the T:A base-pair
in a favorable trajectory for H-bonding interactions (Figure 4.6). As such, the diacylhydrazine
linkage is anticipated to mimic the structure and function of the loop domain, facilitating the
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formation of the closing T:A base-pair. In this manner the diacylhydrazine-linked dinucleoside
would form the smallest shDNA mimic reported to date. The solution-phase synthesis strategy is
based on generating the 5’-semicarbazide-derived deoxyadenosine and the 3’-carboxy-derived
thymidine as building blocks for the ensuing coupling reaction which generates the desired
diacylhydrazine-linked T:A dimer. A synthetic strategy is outlined in this chapter and progress
towards its synthesis is reported. Niki Rana, a graduate student in Dr. David Sabatino’s group is
currently pursuing the total synthesis of the coveted diacylhydrazine-linked T:A dimer for
structure-activity relationship studies. Structure analyses by molecular modeling provides a
preliminary insight on the nature and stability of the turn conformation induced by the
diacylhydrazine linkage. Moreover, the dinucleoside bend is also expected to align the T:A basepair for favorable Watson-Crick H-bonding interactions. With the ultimate goal of generating
high affinity and selective small molecule inhibitors of the Glucose Regulated Protein of 78
kilodalton (GRP78) molecular docking is explored. The generation of potent GRP78 inhibitors
has potential anti-cancer implications. Thus, the diacylhydrazine-linked dinucleoside reported for
the first time in this thesis represents an exciting new class of shDNA mimics that may be useful
for pre-organizing important DNA secondary structures that are related to their biological and
therapeutic activity.
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4.3

STABILIZING

TURN

CONFORMATIONS

IN

DNA

HAIRPINS

BY

DIACYLHYDRAZINE-LINKED NUCLEIC ACIDS
4.3.1 ABSTRACT
The hairpin secondary structure is a prevalent motif found in naturally occurring DNA and
RNA. DNA hairpins have been associated with the regulation of gene expression, modulating
protein function and dictating the activity of mobile genetic elements. Thus, the study of DNA
hairpins and their related analogs may provide greater insight into their evolution, function and
potential in medicinal chemistry applications. The latter forms the basis of this thesis chapter,
which aims to develop short hairpin DNA (shDNA) mimics as regulators of protein function for
therapeutic applications. Our target is the Glucose Regulated Protein 78 (GRP78), which is
overexpressed and exclusively found on the cell surface of tumors. Cell surface GRP78 has thus
been classified as a clinically relevant biological marker for tumor therapy. Therefore, potent
inhibitors of GRP78 may formulate the basis of effective anti-cancer strategies. The fruitful
applications of shDNA in medicinal chemistry applications must address its poor
pharmacokinetic properties and improve its ‘drug-like’ behavior. To this effect, the replacement
of the native 3’,5’-phosphodiester bond with a novel 3’,5’-diacylhydrazine linkage is proposed to
improve shDNA structural stability and pre-organize the turn-like loop geometry. Based on our
preliminary molecular docking studies, the proposed diacylhydrazine-linked shDNA exhibits
tight GRP78 binding at the active site that is also occupied by ATP. This observation is partly
due to the folded geometry of the diacylhydrazine-linked shDNA which pre-organizes a turn
conformation due to the repulsive hydrazine nitrogen lone-pair interactions. This bio-active
structure is anticipated to supply a new class of potent and selective GRP78 competitive
inhibitors.
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4.3.2. INTRODUCTION

The DNA hairpin may differ in structure and function based on the length of the stem, the
size of the loop and in actual nucleotide sequence. It can function to guide DNA folding events
that are associated with protection from degradation, recognition sites for DNA binding proteins
or for controlling gene expression in bacterial and mammalian cells [1]. Although relatively
stable, shDNAs sometimes have the tendency to unfold [2], undergo hydrolysis [14] and nuclease
digestion [15], limiting their overall efficacy as therapeutic agents and as useful ligands for
controlling oncogene expression in-vivo [16,17]. Therefore, structural modifications that may
stabilize hairpin conformation and provide resistance to degradation may improve the structurefunction properties of shDNA. To this effect, alkyl and/or aromatic modifications of the loop
domain found within shDNA have displayed varying effects on hairpin thermodynamic stability,
limiting their potential in medicinal chemistry applications [10-13]. In an effort to improve DNA
hairpin structural stability without compromising function and activity, the design of a 3’,5’diacylhydrazine backbone linkage as replacement of the native 3’,5’-phosphodiester bond is
proposed (Figure 4.4).
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Figure 4.4. Structures of phosphodiester, 4.18 and diacylhydrazine, 4.19, linked T:A dimer

The anticipated turn structure in 3’,5’-diacylhydrazine-linked DNA, 4.19, is based on the
conformational analyses of diacylhydrazines [18-22] and their incorporation within bio-active
peptide sequences, i.e. azapeptides [23-26]. Diacylhydrazine structural analyses by NMR
spectroscopy has indicated a twisted energy minimum conformation, with a large torsional
barrier (>20 kcal/mol in some cases) that locks the turn geometry in a ground state energy
minimum [19,20]. Furthermore, steep rotational barriers (~10 kcal/mol) for the inter-conversion
of E,E and E,Z-configurations about the N-Nα hydrazine bond have been determined by
computational analyses and underscore the stable turn geometries induced by the
diacylhydrazine moiety [18]. These conformational preferences have been attributed to the lone
pair repulsion interactions of the adjacent hydrazine nitrogen atoms which favor a twisted
geometry [18-20]. Moreover, a natural bond orbital (NBO) analysis of N,N’-diformylhydrazine
suggests that exchange of delocalization energy about the hydrazine functional group is partly
involved in the pre-organized diacylhydrazine structure [21]. Furthermore, the rigid urea has
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been found to stabilize the twist structure found within diacyhydrazine containing
pseudopeptides [22]. The incorporation of diacylhydrazines within bio-active peptide sequences
(i.e. azapeptides) have been shown to restrict the backbone torsion angles (90° for φ and 0° or
180° for ψ) for stabilizing peptide turn secondary structures [23-26]. In light of the
diacylhydrazine twist and urea planarity, a turn-like geometry is expected to facilitate the
thymine:adenine (T:A) loop closing interactions in the proposed shDNA mimic, 4.19. This
analog represents a new entry point into privileged shDNA structures that may be useful in a
variety of biological and medicinal applications.
The Glucose Regulated Protein 78 (GRP78) has been classified as a biological target for
therapeutic use due to its involvement in the unfolded protein response (UPR) and cell surface
signaling activity in tumors [27]. GRP78 was first discovered as a 78,000 Da protein whose
expression was enhanced in glucose deprived tissue cultures [28]. Subsequently, GRP78 was
determined to be an ER resident protein, assisting in protein folding events due to a variety of
environmental and physiological stress conditions that perturb ER function and homeostasis [29].
In cancer, GRP78 is overexpressed and exclusively found on the cell surface where it signals
tumor initiation, replication and metastatic spread [30]. Therefore, potent inhibitors of cell
surface GRP78 may formulate the basis of effective and selective anti-cancer strategies.
Small molecule GRP78 inhibitors have been prepared for anti-cancer applications
(Figure 4.5). The natural products, epigallocatechin gallate, (4.20, EGCG), and honokiol, (4.21,
HNK), extracted from green tea leaves and magnolia grandiflora, respectively, have been shown
to induce ER stress leading to potent cell death effects in melanoma, glioblastoma and
neuroblastoma by binding to the GRP78 ATPase domain and inhibiting its activity [31]. A
library of synthetic adenosine-based inhibitors have been prepared by combinatorial chemistry
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and screened against the GRP78 ATP binding domain [32]. The lead inhibitor, 4.22, maintained
potent (KD: 60 nM) and selective GRP78 binding affinity when screened against homologous
heat shock proteins leading to potent cell death across a panel of 10 human cancer cell lines
[32,33]. A fungal metabolite, Verrucosidin (4.23, VCD) with putative GRP78 inhibition,
solicited cytotoxicity in breast cancer cell lines by eliminating cellular mitochondrial energy
production [34]. This finding has generated conjecture that other claimed GRP78 inhibitors
(arctigenin, biguanides, deoxyverrucosidin, efrapeptin, JBIR, piericidin, prunustatin, pyrvinium,
rottlerin, valinomycin, versipelostatin) might act in a GRP78-independent manner. The small
molecule GRP78 inhibitors, 4.20-4.23, may form the basis for the rational design of novel
GRP78 inhibitors for potent and selective anti-cancer activity.

Figure 4.5. Small molecule GRP78 inhibitors [31-34].
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4.3.3. RESULTS AND DISCUSSIONIn order to explore the putative turn-like geometry
within diacylhydrazine-linked shDNA, 4.19, molecular modeling and docking simulation studies
were respectively performed using Chem3D molecular mechanics and Autodock Vina [35]. The
energy minimized structures were then visualized using PyMOL [36]. A comparative energy
minimization study was initially performed in between the native phosphodiester, 4.18 and
diacylhydrazine, 4.19 linked T:A dimers (Figure 4.6) to explore the influence of the backbone
modification on molecular structure. Based on the preliminary energy minimization data, the
native T:A dimer exhibits a stacked orientation that is most likely stabilized by the hydrophobic
aromatic interactions of the non-pairing nucleobases (Figure 4.6, A). In comparison, the 3’,5’diacylhydrazine linkage functions to pre-organize the molecular structure into a turn-like
geometry that is reminiscent of the non-pairing loop domain found within shDNA (Figure 4.6,
B). The observed turn structure in 4.19, is most likely pre-organized by the repulsive hydrazine
nitrogen lone-pair interactions and the rigid, planar urea which tends to favor a perpendicular
geometry by bending the diacylhydrazine in a (Z,E)-conformation [18-22]. Furthermore, the
turn-like geometry is also stabilized by the intramolecular H-bonding T:A base-pairing
interactions. These have been found to occur within optimal spatial distances (<5 Å) in the
diacylhydrazine-linked T:A dimer and not within the native sequence (>10 Å). Therefore, the
turn-type conformation in shDNA mimic, 4.19, has been found to be energetically stabilized by a
combination of favorable stereoelectronic and bonding interactions. These effects are typically
significant in minimizing the free energy (ΔGB≠) associated with ligand binding to target receptor
for fruitful medicinal chemistry applications [32,33].
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Figure 4.6. Structures and models of A. (ApT), native DNA, 4.18 and B. 3’,5’-diacylhydrazine
linked T:A, 4.19. Molecular models were calculated using Chem3D molecular mechanics
software and represented as energy minimized structures using the MM2 force field with a
minimum RMS gradient of 0.01. The energy minimized structures were analyzed and the Hbonding distances were determined using PyMol.

AutoDock Vina [35] was next employed as computer docking simulations program to
predict the GRP78:4.19 binding interactions. The co-crystal structure of ATP bound to the
ATPase domain of GRP78 was freely downloaded from RCSB PDB (PDB ID # 3LDL)
[32,33,37]. An interface between the molecular graphics system PyMOL and the molecular
docking suite AutoDock Vina was used to demonstrate the combination of docking and
visualization models in between the ligand 4.19 and the GRP78 binding domain. The energy
minimized structure of 4.19 was imported into AutoDock Vina and docked onto the ATPase
binding domain of GRP78. The energy minimum conformation responsible for GRP78 binding
(root mean square deviation; rmsd = 0) was selected from the output file (Table 4.1).
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Distance from best mode
Affinity
Mode
(kcal/mol)
1
2
3
4
5
6
7
8
9

-9.3
-9.3
-9.2
-8.8
-8.8
-8.7
-8.7
-8.7
-8.5

Rmsd l.b.

Rmsd u.b

0
2.61
2.699
2.767
3.208
2.556
1.419
3.271
2.667

0
5.95
6.743
5.226
6.807
3.58
2.057
8.731
6.21

Table 4.1. Energy minimized conformations of 4.19 bound to GRP78. Lamarckian genetic
algorithms, as implemented in AutoDock Vina [35], were employed to perform the docking
simulation studies. All other parameters were retained as default settings. By default, AutoDock
Vina generate 10 best binding mode at receptor site. For each of the docking cases, the lowest
energy docked conformation, according to the AutoDock scoring function, was selected as the
binding mode.

Significantly, ligand 4.19 demonstrated comparable GRP78 binding affinity when
compared to the literature reported adenosine-derived inhibitors, 4.22 [32,33]. Moreover, ligand
4.19 was found to occupy the ATPase binding site of GRP78, supporting its potential as a potent
and selective GRP78 inhibitor (Figure 4.7). Comparison of the co-crystal structures of GRP78
and its related homologue HSP70 in the presence of their bound ligands indicated a conserved
ATPase binding domain, with the exception of a single amino acid residue (GRP78 : Ile61 and
HSP70 Thr37) [32,33,38]. This single amino acid substitution is sufficient in discriminating
between the two chaperone proteins. Moreover, this structural feature has been exploited in the
design of GRP78 selective inhibitors [32,33]. The non-polar Ile61 in GRP78 creates a
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hydrophobic binding pocket that can accommodate ligands with non-polar and small electronrich groups (eg. NH-, OH-, SH-). This interaction has facilitated the binding of ligand 4.19
within the same proximity (<6 Å) as the naturally occurring ATP ligand (Figure 4.8). Thus, a
combination of conformational pre-organization and non-polar interactions has enabled tight
binding of ligand 4.19 to the GRP78 ATPase active site, making it a potential lead in the
development of high affinity and selective GRP78 inhibitors.

Figure 4.7. Docking of diacylhydrazine linked T:A dimer, 4.19 on the GRP78:ATP complex
(PDB: 3LDL) (GRP78: Red, ATP: White, 4.19: multicolor, ATPase binding site: yellow).
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Figure 4.8. Expansion of the docking interaction of diacylhydrazine linked T:A dimer, 4.19 on
the GRP78:ATP complex (PDB: 3LDL) (GRP78: Red, ATP: White, 4.19: multicolor, ATPase
binding site: yellow). ATP and 4.19 are positioned within a 6 Å distance from the Ile61 residue
located at the ATPase active site.

The synthesis strategy for the production of the diacylhydrazine-linked T:A dimer, 4.19,
is currently on-going in collaboration with Niki Rana, a graduate student in Dr. David Sabatino’s
research group. The proposed synthesis method is outlined, with a detailed description of the
synthetic steps that have been successfully completed. The synthesis of the desired ligand 4.19
is contingent on the generation of a 3’-carboxy derived thymidine, 4.32, and a 5’-semicarbazidederived deoxyadenosine, 4.28, that may be coupled to form the target diacylhydrazine-linked
T:A dimer, 4.19 (Scheme 4.3).
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The synthesis of the 5’-semincarbazide derived deoxyadenosine, 4.28 begins with the
attachment of a carboxybenzyloxy (Cbz) protecting group at the 3-position of commercially
available N-acetyl-5’-O-(4-dimethoxytrityl) deoxyadenosine, 4.24. (Scheme 4.1). The Cbz
protecting group was easily installed using benzylchloroformate and DMAP in DCM [39].
Following carbomylation, 4.25 was detritylated using 3% trichloroacetic acid giving 4.26 in 98%
yield. The 5’-alcohol was next oxidized to the corresponding carboxylic acid, 4.27, using a
BAIB-TEMPO oxidation reaction [40]. Due to difficulty in purification and very high polarity of
carboxylic acid, this product was coupled to Boc-carbazate using conventional peptide coupling
conditions [41]. Finally, attempts to remove BOC protecting group on carbazate to liberate free
NH2 using conventional TFA:DCM (50:50) led to a series of degradation products. Currently, we
are optimizing the reaction and purification conditions for the synthesis of 4.28.
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Scheme 4.1. Synthesis of N-acetyl 5’-semicarbazide 3’-carboxybenxyloxy deoxyadenosine,
4.28. Reactions and Conditions. (a) DMAP, benzyl chloroformate, DCM, 0 oC - rt, 72 h, (b) 3%
TCA:DCM, rt, 15 min, (c) TEMPO, BAIB, MeCN:H2O (50:50 v/v), rt, 15 h, (d) i. t-butyl
carbazate, EDC, Oxyma, DIEA, DCM, rt, 12 h, ii. 50% TFA:DCM, rt, 2 h.

The synthesis of a 3’-carboxy-derived thymidine 4.32, also proved challenging (Scheme
4.2). The first attempted O-alkylation reactions of commercially available 5’-O-(4dimethoxytrityl) thymidine 4.29 with ethyl bromoacetate, methyl bromoacetate, phenyl
bromoacetate and Boc-bromoacetate failed to yield the desired product. In spite of the alkylating
reagent and reaction conditions, the N-alkylated nucleosides were isolated as major products due
to enhanced nucleophilicity at the N3 position of thymine. Following literature precedence, an
allylation strategy was adopted to circumvent N-alkylation and afford the desired 5’-O-(4dimethoxytrityl) 3’-O-allyl thymidine 4.30 [42]. In our hands, the reaction of thymidine 4.29
with allyl bromide under ultrasonic conditions gave the desired product 4.30 in 77% yield.
Oxidative cleavage of the allyl group using OsO4 then allowed for the formation of aldehyde
4.31 in 92% yield. Radical oxidation conditions [40] (TEMPO-BAIB) were next employed to
convert the 3’-aldehyde to the corresponding carboxylic acid 4.32. Considering the difficulty
associated with the purification of carboxylic acid 4.32 using normal phase silica gel
chromatography and the acid sensitivity of the dimethoxytrityl (DMT) group, carboxylic acid
4.32 was not isolated and characterized. A modified protecting group strategy is currently being
investigated for the stable production of building block 4.32.
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Scheme 4.2. Synthesis of 5’-O-(4-dimethoxytrityl) 3’-O-(carboxymethylene) thymidine, 4.32.
Reactions and Conditions. (a) allyl bromide, NaH, THF, rt, 3 h, (b) OsO4, NMO, NaIO4,
Na2S2O5, acetone:phosphate buffer (3:1 v/v) pH 7, rt, 5 h, (c) TEMPO, BAIB, MeCN:H2O
(50:50 v/v), rt, 2 h.

With isolated building blocks in hand, the coupling reaction in between the 5’semicarbazide derived deoxyadenosine, 4.28 and the 3’-carboxy derived thymidine, 4.32 will be
next attempted. Conventional couping reagents such as EDC/Oxyma, HATU and EEDQ will be
tried to afford the protected 3’,5’-diacylhydrazine linked T:A dimer, 4.33. The ensuing steps will
consist of the selective removal of the protecting groups to afford the anticipated 3’,5’diacylhydrazine linked T:A dimer, 4.19, (Scheme 4.3).
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Scheme 4.3. Proposed synthesis of the 3’,5’-diacylhydrazine linked T:A dimer, 4.19.

4.3.4. CONCLUSIONS
In summary, a novel class of backbone modified DNA has been introduced within this
chapter. The 3’,5’-diacylhydrazine linked T:A dimer is proposed to mimic shDNA structure and
activity. The diacylhydrazine pre-organizes a turn-type geometry which favors the closing T:A
base-pairing interactions according to computational analyses. This privileged structure was
docked onto the GRP78 oncoprotein and demonstrated tight binding at the ATPase active site
also occupied by the ATP ligand. These in silico studies demonstrate the potential for shDNA
mimic 4.19 to bind and inhibit cell surface GRP78 activity. This is an essential requirement for
the development of potent and selective GRP78 inhibitors for anti-cancer applications. Thus,
diacylhydrazine-linked nucleic acids represent a new class of privileged structures that may
mimic biologically active turn conformations for structure-activity relationship studies.
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4.3.5. EXPERIMENTAL SECTION
Methods. All reactions were carried out in oven dried (120 oC) glassware and purged with
nitrogen. Syringes and needles were stored in an oven overnight and allowed to cool in
desiccators with anhydrous calcium sulfate prior to use. Reactions were stirred with Teflon
coated magnetic stir bars. Reactions were monitored using Thin Layer Chromatography (TLC)
on aluminum-backed silica gel plates (Merck 60 F254). TLC plates and were visualized under
UV light (260 nm) and by staining with 10% H2SO4 in MeOH. Compound purification using
silica gel chromatography was performed on a 230-400 mesh silica (Sorbent Technologies).
Anhydrous solvents and reagents were purchased from Aldrich (St. Louis, MO) and VWR
(Bridgeport, NJ). Melting points were measured on a Thermo Melt apparatus. Specific rotations
measurements were recorded on a DigiPol 781 Automatic Polarimeter (Rudolph Instruments,
Fairfield, NJ, USA) as averages of five measurements. Data are reported as follows: [α]λ temp,
concentration (c in g/100 mL), in Ace, MeOH, DCM or CHCl3. Molecular weights were
measured as direct injections on a Hewlett Packard series 1100 MSD equipped with ESI as ionsource in positive mode using 50/50 v/v MeOH/H2O at a flow-rate of 1 mL/min. Infrared (IR)
spectra were obtained on a Nicolet 4700 FT-IR (ThermoElectron Co.) coupled with OMNIC
software (driver version: 7.1). Samples were prepared on a KBr plate using a cast film technique
and the spectrum was recorded by monitoring the change in sample transmittance as a function
of wavenumbers (cm-1). IR spectra were collected in triplicate to ensure reproducibility. Nuclear
magnetic resonance spectra (1H, 13C, COSY NMR) were recorded on an OXFORD NMR AS500
spectrophotometer with sample dissolved in deuterated chloroform (CDCl3), dichloromethane
(CD2Cl2), acetone (acetone-d6) and dimethylsulfoxide (DMSO-d6). The NMR spectra were
obtained at ambient temperature using an indirect pulse-field gradient (ID-PFG) probe. The
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obtained data was processed using VNMRJ software (version 2.2). The 1H and 13C assignments
were based on gCOSY and gHMQC NMR correlation experiments.

N-Acetyl-5’-O-(4-dimethoxytrityl)-3’-O-(carboxybenzyloxy)

deoxyadenosine,

Acetyl-5’-O-(4-dimethoxytrityl)

mmol)

deoxyadenosine

(2g,

3.36

was

4.25.

N-

suspended

in

dichloromethane (20 mL) and DMAP (1.36 g, 11.13 mmol) was added. After cooling at 0 ºC,
benzyl chloroformate (1.39 mL, 9.24 mmol) was added dropwise and the suspension was stirred
at room temperature overnight. The next day, the solution was diluted in dichloromethane (10
mL) and evaporated to a viscous oil. The product was purified by silica gel chromatography
(Acetone/DCM 1:9 v/v) giving 4.25 (1.90 g) as a white solid. Yield: 77%. m.p. 89 ºC. Rf = 0.55
(CH2Cl2–Acetone, 9:1), [α]D22 -3.709 (c 0.80, DCM). 1H NMR (500 MHz, CD2Cl2): δ 1.45 (d, J
= 0.9 Hz, 3 H), 2.39 (ddd, J = 6.0, 8.5, 14.2 Hz, 1 H), 2.50 (ddd, J = 2.3, 6.0, 14.2 Hz, 1 H),
3.41–3.43 (m, 2 H), 3.79 (s, 6 H), 4.20–4.22 (m, 1 H), 4.27 (s, 2H), 4.46–4.48 (m, 1 H), 6.33 (dd,
J = 6.0, 8.5 Hz, 1 H), 6.90–6.92 (m, 4 H), 7.25–7.37 (m, 7 H), 7.48–7.50 (m, 2 H), 7.60 (d, J =
0.9 Hz, 1 H), 9.64 (s, 1 H), 10.01 (s, NH).
13

C NMR (500 MHz, DCM-d6): δ = 12.2 (CH3 T), 38.0 (C-2′), 55.5 (OCH3 DMT), 64.8 (C-5′),

75.4 (OCH2), 81.7 (C-3′), 84.7 (C-4′), 87.5 (Cq), 87.6 (C-1′), 111.1 (C-5), 114.0, 127.8, 128.8,
129.0 and 131.0 (5 × C-Ar), 136.4 (C-6), 145.9 (Cq), 151.3 (C-2), 159.6 (Cq), 164.2 (C-4), 200.6
(CHO)
ESI MS (m/z) calculated for C40H37N5O9 [M-H], 730.26; found 730.00
IR (KBr) υmax (cm-1) 3267.9, 3055.3, 2930.3, 2359.9, 1745.4, 1700.8, 1609.1, 1509, 1461,
1373.8, 1295.7, 1247.7, 1178.6, 1074.9, 1034.4, 942.3, 831, 790.5, 730.6, 701.5, 645.3.
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N-Acetyl-3’-O-(carboxybenzyloxy) deoxyadenosine, 4.26. To compound 4.25 (1.8 g, 2.4
mmol) was added 3% trichloroacetic acid in dichloromethane (134 mL, 3.6 mmol) at room
temperature. The reaction was continued for an additional 15 minutes until TLC indicated
reaction completion. The solution was diluted in dichloromethane (10 mL) and concentrated to a
dark yellow residue. The pure product was isolated following purification by silica gel column
chromatography (Acetone/DCM 2:8 v/v) giving 4.26 (500 mg) as a white solid. Yield: 87% TLC
(Acetone/DCM 2:8) Rf : 0.23. m.p. 79 ºC. 1H NMR (499.84 MHz, DMSO-d6): δ 10.84 (s, NH),
11.61 (s, NH), 8.7-8.6 (s, 2H), 7.3-7.4 (m, 6H), 6.47 (d, J = 8.7 Hz, 1H), 5.37 (dd, J = 5.49, 5 Hz,
1H), 5.2 (t, J = 5Hz, 1H), 5.14 (d, J = 11 Hz, 2H), 5.07 (d, J = 2Hz, 2H), 4.18 (brs, 1H), 3.7 (dd,
J = 10, 5 Hz, 2H),3.07(dd, J=17.89 Hz), 2.63 (m, 1H),

13

C NMR (125.699 MHz, DMSO-d6): δ

169.5, 165.5, 154.2, 152.1, 152.0, 151.9, 150.0, 143.2, 135.7, 128.8, 85.6, 84.2, 79.35, 70.6,
69.74, 61.90, 61.820, 40.0. IR(KBr) υmax (cm-1) 3572.1, 3400.3, 1736.0, 1700.5, 1658.3, 1649.7,
1641.3, 1631.0, 1620.0, 1612.7, 1555.7, 1537.9, 1462.6, 1381.7, 1331.3, 1266.9, 1101.0, 938.8,
787.9, 698.4.
MS: [M-H] found 426.26 found 427.0

N-Acetyl-5’-carboxy-3’-O-(carboxybenzyloxy)

deoxyadenosine,

4.27.

N-Acetyl-3’-O-

(carboxybenzyloxy) deoxyadenosine, 4.26 (0.4 g, 0.84 mmol), TEMPO (27 mg, 0.17 mmol) and
bis(acetoxy)iodobenzene (BAIB) (547 mg, 1.70 mmol) were dissolved in MeCN/H2O (1:1 v/v, 8
mL) and stirred for an additional 3 h at room temperature (22 oC). Following complete reaction,
the mixture was diluted in EtOAc (15 mL), washed with brine (2 x 15 mL) and extracted with
EtOAc (2 × 15 mL). The combined organic extracts were dried over MgSO4 and concentrated to
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a yellow solid (325 mg, 79%) without the need for purification. TLC (MeOH/DCM 1:9 v/v) R f :
0.1. IR(KBr) υmax (cm-1) 3591.1, 3571.7, 3452.0, 1658.1, 1641.2, 1631.0, 488.4. ESI- MS M/Z
Calculated for [M-H] 443. Found [M-H] 443 g/mol

5’-O-(4-dimethoxytrityl) 3’-O-allyl thymidine, 4.30. To a suspension of 60% NaH (182 mg,
4.55 mmol) in anhydrous THF (10 mL) was added 5’-O-(4-dimethoxytrityl) thymidine, 4.29
(988 mg, 1.82 mmol) under argon at 0 °C. The mixture was sonicated for 20 min, and allyl
bromide (400 μL, 9.1 mmol) was added to the reaction mixture which was stirred for an
additional 3 h at room temperature (22 oC). The mixture was poured into saturated NaHCO3 (20
mL) and extracted with EtOAc (3 × 20 mL). The combined organic extracts were washed with
brine (30 mL), dried over MgSO4, filtered and concentrated in vacuo. Purification by flash
column chromatography (EtOAc–petroleum ether, 1:1 v/v, 1% Et3N) afforded 4.30 as a white
solid; Yield: 954 mg, 90%;
m.p. 83 °C. [α]D22 +16.2 (c 0.90, acetone). Rf = 0.55 (EtOAc–petroleum ether, 7:3 v/v).
1

H NMR (500 MHz, acetone-d6): δ 1.47 (d, J = 1.4 Hz, 3 H), 2.35 (ddd, J = 5.5, 7.8, 13.5 Hz,

1H), 2.41 (ddd, J = 2.5, 6.0, 13.5 Hz), 3.39 (d, J = 3.7 Hz, 2 H), 3.79 (s, 6 H), 4.02 (dd, J = 5.5,
13.3 Hz, 1 H), 4.07 (dd, J = 5.5, 13.3 Hz, 1 H), 4.12–4.14 (m, 1H), 4.37–4.39 (m, 1H), 5.14 (m,
1H), 5.26 (m, 1H), 5.85–5.98 (m, 1H), 6.31 (dd, J = 6.0, 7.8 Hz, 1 H), 6.89–6.93 (m, 4 H), 7.24–
7.39 (m, 7 H), 7.47–7.50 (m, 2 H), 7.61 (d, J = 1.4 Hz, 1 H), 10.0 (s, NH).

13

C NMR (126 MHz,

acetone-d6): δ 12.2, 38.2, 55.5, 64.8, 70.6, 79.9, 84.6, 85.3, 87.5, 111.0, 114.0, 116.9, 127.7,
128.7, 129.0, 131.0, 135.8, 136.5, 145.9, 151.2, 159.7, 164.2. ESI MS (m/z) calculated for
C34H36N2O7 [M+Na], 607.2; found 607.2. IR (KBr) υmax (cm-1) = 3182.1, 3059.1, 2929.9,
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2836.8, 1693.4, 1607.7, 1582.3, 1508.9, 1464.5, 1364, 1273.5, 1251.1, 1177.1, 1105.4, 1063.1,
1033.5, 915.8, 829.1, 791.1, 755.8, 727.0, 702.1.

5’-O-(4-dimethoxytrityl)-3′-O-(formylmethylene) thymidine, 4.31. 5’-O-(4-dimethoxytrityl)
3’-O-allyl thymidine, 4.30 (1.63 g, 2.79 mmol) was dissolved in a mixture of acetone–H2O (3:1
v/v, 12 mL). NMO (0.65 g, 5.58 mmol) and 2% OsO4 in H2O (1.8 ml, 7.0 mmol) was added and
the mixture was stirred for 2 h at room temperature (22 oC) until TLC indicated complete
consumption of starting material. Na2S2O5 (0.98 g, 1.6 mmol) was then added and the reaction
mixture was stirred for 30 min. The reaction was quenched with H2O (50 mL) and the aqueous
layer was extracted with EtOAc (3 × 50 mL). The combined organic extracts were washed with
brine (100 mL), dried over MgSO4, filtered and concentrated in vacuo. The residue was
dissolved in a mixture of acetone–phosphate buffer pH 7 (3:1 v/v, 22 mL), and NaIO4 (1.50 g,
7.02 mmol) was added. The mixture was stirred at room temperature for 2 h, filtered, and the
precipitate was washed with EtOAc (50 mL). The aqueous layer was extracted with EtOAc (2 ×
50 mL) and the combined organic extracts were washed with brine (100 mL), dried over MgSO4,
filtered and concentrated. The crude product 4.31 (off white solid; 1.64 g, >90%) was isolated
without further purification. m.p. 123 °C; [α]D22 +3.61 (c 0.80, acetone); Rf = 0.55 (CH2Cl2–
MeOH, 9:1 v/v).
1

H NMR (500 MHz, acetone-d6): δ 1.45 (d, J = 0.9 Hz, 3 H), 2.39 (ddd, J = 6.0, 8.5, 14.2 Hz,

1H), 2.50 (ddd, J = 2.3, 6.0, 14.2 Hz, 1H), 3.41–3.43 (m, 2H), 3.79 (s, 6 H), 4.20–4.22 (m, 1 H),
4.27 (s, 2H), 4.46–4.48 (m, 1 H), 6.33 (dd, J = 6.0, 8.5 Hz), 6.90–6.92 (m, 4H), 7.25–7.37 (m,
7H), 7.48–7.50 (m, 2 H), 7.60 (d, J = 0.9 Hz, 1 H), 9.64 (s, 1H), 10.0 (s, NH). 13C NMR (500
MHz, acetone-d6): δ = 12.2, 38.0, 55.5, 64.8, 75.4, 81.7, 84.7, 87.5, 87.6, 111.1, 114.0, 127.8,
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128.8, 129.0 and 131.0, 136.4, 145.9, 151.3, 159.6, 164.2, 200.6; ESI MS (m/z) calculated for
C33H34N2O8 [M+H], 586.23; found 585.2; IR (KBr) υmax (cm-1) = 3307, 3066.8, 3007.3, 2953.4,
2929.6, 2856.5, 1736.7, 1698.6, 1660.3, 1610.8, 1557.2, 1509.6, 1485.4, 1445.8, 1382.6, 1300.8,
1253.5, 1217.4, 1176.1, 1109.9, 1072, 1034.8, 1002.6, 968.5, 936.6, 890.7, 863.6, 755.8, 704.6,
667.9

Molecular modeling. MGL tools 1.5.4 with Autodock tools and AutoDock Vina [35] were used
create and perform blind docking calculations between the GRP78 ATPase binding domain in
complex with ATP (PDB: 3LDL) and the 3’,5’-diacylhydrazine linked T:A dimer, 4.19. The
molecular models were prepared using AutoDock Tools in PDBQT format. The GRP78 protein
was enclosed in a box with the number of grid points located in the x × y × z directions, 70 × 86
× 120 and with a grid spacing of 0.375 Å. The center of the grid was set to 14.719, 20.979, and
8.824 Å. Lamarckian genetic algorithms, as implemented in AutoDock Vina [35], were
employed to perform the docking simulation studies. All other parameters were retained as
default settings. For each of the docking cases, the lowest energy docked conformation,
according to the AutoDock scoring function, was selected as the binding mode. The output from
AutoDock Vina was analyzed using PyMol [36].
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CHAPTER 5: CONCLUSIONS AND CONTRIBUTIONS TO KNOWLEDGE
5.1 CONCLUSIONS AND CONTRIBUTIONS TO KNOWLEDGE MADE IN THIS
THESIS

5.1.1 Aminoacyl Nucleolipids as DNA Binding Molecules with Anti-Leukemic Activity
The second chapter of this thesis focused on the synthesis and characterization of a series
of nucleic acid bioconjugates. The goal of this work was to explore the ability of an aminoacyl
nucleolipid bioconjugate to bind to oncogenic DNA sequences and exhibit anti-cancer activity.
Towards this research aim, a small library of nucleoside bioconjugates with amino acyl, alkyl
amino, alcohol and glycol groups were prepared by a simple, yet versatile synthetic procedure.
This included the preparation of a novel N-isobutyryl 5’-carboxy 2’,3’-bis-O-(carbobenzyloxy)
guanosine, which served as a useful building block for further diversification. Among the
synthesized nucleoside bioconjugates, the aminoacyl nucleoside, with a suitably protected lysine
group was extended to the putative aminoacyl nucleolipid following the attachment of the
palmitoyl groups. Following selective lysine deprotection under acidic conditions, a highly
functionalized cationic nucleolipid was tested for its ability to bind to a GRP78 oncogene and
trigger potent cell death activity in cancer. Firstly, the promoter region of GRP78 DNA was
synthesized using an ABI 3400 DNA synthesizer. Following GRP78 DNA isolation, binding
experiments using gel shift assays, thermal denaturation, CD spectroscopy and dynamic light
scattering validated the DNA binding capabilities of the aminoacyl nucleolipid synthesized in
this study. In order to assess its anti-cancer activity, the molecule was selected in the NCI’s 60
cancer cell line screen (http://dtp.nci.nih.gov/). Its bioactivity profile was investigated among a
panel of 60 cancer cell types at a single dose (10 µM) experiment. Results showed greater than
90% cell death in a single human leukemia cell line (SR-91) from the panel of 60 different
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cancer cell types tested. The reported aminoacyl nucleolipid thus represents a useful model for
building DNA binding molecules and for the development of potent and selective anti-cancer
agents. The significance of this work has been recognized by a recent publication in Bioorganic
Medicinal Chemistry Letters and sets the stage for future work on the aminoacyl nucleolipid
scaffold and its unprecedented anti-cancer activity.

5.1.2 A Fluoroalkyl Phthalocyanine-Cancer Targeting Oligonucleotide Bioconjugate and its
Oncogene Photocleavage Activity
The third thesis chapter reported for the very first time, a chemically robust
photosensitizer, the fluoroalkyl phthalocyanine, conjugated with a cancer targeting
oligonucleotide (CTO) to seek and destroy oncogenes in the presence of light and oxygen. This
feat was accomplished by the preparation of an asymmetric perfluorophthalocyanine (Pc)
bearing a carboxylic acid group for bioconjugation with a CTO. The preparation of the Pc was
performed by a zinc-promoted macrocyclization reaction of pthalonitrile precursors under
microwave radiation. Following exhaustive silica gel chromatographic purification, analyses by
NMR, UV-Vis and HRMS, this Pc catalyst demonstrated long-lasting (t1/2 = 43 min) singlet
oxygen generation without self-decomposition in the photooxidation of β-citronellol. This Pc
photosensitizer was then coupled to an antisense oligonucleotide targeting the GRP78 oncogene
for applications in cancer-targeted photodynamic therapy (PDT). The complex demonstrated the
ability to hybridize to the sense strand of GRP78 DNA and mRNA sequences to afford the
putative PcDNA:DNA and PcDNA:mRNA hybrids. These complexes demonstrated good
solubility in physiologically relevant phosphate buffer leading to the formation of stable hybrid
duplexes (Tm: 75, 72 oC, respectively) as discerned from thermal denaturation experiments. In a
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photooxidation and piperidine cleavage assay, PcDNA and PcDNA:mRNA hybrids
demonstrated time-dependent (12 h) oligonucleotide degradation, highlighting their potential in
cleaving oncogenes in a sequence specific manner. The photoactive and chemically robust
fluorophthalocyanine-CTO bioconjugates thus encompass a new class of potential anti-cancer
agents. The impact of this work has been recognized by a featured article in the journal of
Chemical Communications. Our publication was selected as the journal cover story, which
featured a depiction of our infamous McNulty Atom Wall shedding light and oxygen into a Pc
substrate which induced potent degradation of an oncogene target (Figure 3.3).

5.1.3 The Diacylhydrazine DNA Turn
In chapter four of this thesis, a new class of DNA backbone modification is presented.
The replacement of the native 3’,5’-phosphodiester bond for a 3’,5’-diacylhydrazine linkage is
proposed to stabilize the turn-type conformation found within the loop domain of short hairpin
DNA, shDNA. Considering the hairpin is a prevalent secondary structure found within DNA and
RNA, mimics that may stabilize hairpin structure and function may have widespread utility in
biology and medicine. The N,N’-diacylhydrazine functional group is especially useful in
stabilizing turn-type geometries in small molecules and peptides. Our goal is to establish
structural trends that may lead to important biological applications for diacylhydrazine
containing nucleic acids.
The molecular modeling for a diacylhydrazine linked T:A dimer indicated a turn-type
geometry that was contingent on the influence of the diacylhydrazine moiety. The
diacylhydrazine tends to favor a turn-type geometry due to the repulsive stereoelectronic effects
of the nitrogen lone pairs which bends the nucleic acid backbone into a turn geometry.

125

Moreover, this turn geometry is stabilized by the rigid urea which places the T:A base-pairs
within hydrogen bonding distances (<5 Å). Furthermore, molecular docking studies of the
diacylhydrazine linked T:A dimer onto the GRP78 oncoprotein demonstrated tight binding at the
ATPase active site also occupied by the ATP substrate. These in silico studies demonstrate the
potential for shDNA mimic 4.19 to bind and inhibit cell surface GRP78 activity. Inhibition of
GRP78 signaling in cancer has shown anti-proliferative effects in malignant tumors en route
towards the development of effective anti-cancer strategies. Intrigued by its promising structureactivity profile, the synthesis of the diacylhydrazine linked T:A dimer was attempted. Progress
towards the synthesis of the pre-requisite A and T building block nucleic acids for the generation
of the target shDNA mimic 4.19 have been reported in this thesis. The synthesis strategy is
currently being developed for structure-function studies of the coveted diacylhydrazine linked
T:A dimer. In sum, this diacylhydrazine-linked nucleic acid represents a novel class of structures
that may mimic biologically active turn conformations for important SAR studies.
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